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Key points 
• A high frequency of diverse, activating mutations in co-stimulatory/TCR-related
signaling genes occur in AITL and other TFH-derived PTCL
• Deregulated TCR activation may play a role in the pathogenesis of TFH-derived PTCL,
paving the way for developing novel targeted therapies
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Abstract 
Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from follicular T-
helper cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCL) with 
poorly understood pathogenesis and unfavorable treatment results. We investigated a series of 85 
patients with AITL (n=72) or other TFH-derived PTCL (n=13) by targeted deep sequencing of a 
gene panel enriched in T-cell receptor (TCR) signaling elements. RHOA mutations were 
identified in 51/85 cases (60%) consisting of the highly recurrent dominant negative  G17V 
variant in most cases and a novel K18N in 3 cases, the latter showing activating properties in in 
vitro assays. Moreover, half of the patients carried virtually mutually exclusive mutations in 
other TCR-related genes, most frequently in PLCG1 (14.1%), CD28 (9.4%, exclusively in 
AITL), PI3K elements (7%), CTNNB1 (6%) and GTF2I (6%). By in vitro assays in transfected 
cells, we demonstrated that 9/10 PLCG1 and 3/3 CARD11 variants induced MALT1 protease 
activity and increased transcription from NFAT or NF-kB response element reporters, 
respectively. Collectively, the vast majority of variants in TCR-related genes could be classified 
as gain-of-function. Accordingly, the samples with mutations in TCR-related genes other than 
RHOA had transcriptomic profiles enriched in signatures reflecting higher T-cell activation. 
Although no correlation with presenting clinical features nor significant impact on survival was 
observed , the presence of TCR-related mutations correlated with early disease progression. 
Thus, targeting of TCR-related events may hold promise for the treatment of TFH-derived 
lymphomas.
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Introduction 
Angioimmunoblastic T-cell lymphoma (AITL), one of the most common peripheral T-cell 
lymphomas (PTCL)1,2 comprises CD4-positive neoplastic T cells with a T follicular helper 
(TFH) immunophenotype, and an important reactive microenvironment3.  Additionally, a subset 
of PTCL not otherwise specified (PTCL-NOS) exhibiting a TFH-like immunophenotype and 
overlapping characteristics with AITL, are believed to be part of the same disease spectrum 4,5. 
The prognosis of AITL remains poor, with a 5-year overall survival of around 30% 1,6. Although 
autologous stem cell transplantation may improve the response to conventional first-line therapy, 
early disease progression makes it frequently impossible 7.  Thus, pinpointing new druggable 
targets for developing specific therapies in TFH-derived lymphomas remains critical. 
Recurrent mutations in the epigenetic regulators TET2, IDH2 and DNMT3A have been 
detected in  AITL and TFH-like PTCLs 8,9, but are not likely sufficient to drive 
lymphomagenesis10,11. A highly recurrent dominant-negative G17V mutation in the RHOA 
GTPase was recently discovered in up to 70% of AITL and TFH-like PTCLs 12-14. RHOA is 
activated downstream of T-cell receptor (TCR) engagement in mature T cells and is linked to 
cytoskeleton reorganization following T-cell activation 12,13. Although their exact role in human 
T-cell transformation remains uncertain, RHOA mutations tend to co-occur with TET2 mutations, 
suggesting that they represent a second event in multistep AITL lymphomagenesis15. Finally, 
AITL also bears a variety of other less recurrent genetic alterations12,13,16. 
In B-cell lymphomas, constitutive B-cell receptor (BCR) signaling via somatic mutation-
induced or antigen-mediated activation of key BCR components lead to neoplastic B-cell 
survival and expansion17. Several lines of evidence suggest that TCR activation might be 
similarly relevant to PTCL pathogenesis. For example, NPM1-ALK chimeric proteins induce an 
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intracellular cascade of events substituting to TCR signaling in anaplastic large cell lymphoma 
18
. The ITK-SYK fusion present in rare PTCLs likewise drives lymphomagenesis by triggering
antigen-independent activation of TCR signaling pathways in mice19. Mutations or gene fusions 
in co-stimulatory/TCR signaling genes as CD28, FYN, PLCG1 or CARD11 have also been 
reported in several PTCLs12,20-25. However, alterations in the TCR signaling pathway have not 
yet been extensively studied in TFH-related lymphomas. Here, we focused on investigating 
mutations in the co-stimulatory/TCR signaling cascade in a series of AITL and TFH-like PTCLs 
using a targeted deep sequencing approach. Besides frequent RHOA mutations, we demonstrated 
recurrent activating and virtually mutually exclusive mutations in  co-stimulatory/TCR pathway 
components in 49% of the cases. Notably, we found several mutations in PLCG1 and CARD11 
that we characterized as functionally activating in vitro. Integrated analysis with gene expression 
profiles indicated that TCR-mutated samples were enriched for molecular signatures reflecting 
higher T-cell activation and proliferation. Clinically, TCR-mutated patients receiving 
anthracyclin-based chemotherapy showed an increased early progression risk compared to 
patients without such mutations. These results indicate the potential of using drugs that reduce 
TCR signaling for treating these lymphomas. 
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Methods 
Patients and Tumor Samples 
Discovery cohort: eleven paired tumoral and normal samples from 10 clinically annotated AITL 
patients were subject to whole-genome (WGS, n=8) or whole-exome sequencing (WES, n=3) 
(Table S1).  
Extended cohort: targeted deep sequencing (TDS) was performed on DNA extracted from frozen 
tissue biopsies of an extended cohort of 85 previously untreated patients (72 AITL and 13 TFH-
like PTCL-NOS). In three patients, paired samples were analyzed. These cases and associated 
clinical annotations (Table S2), were collected in the framework of the Tenomic LYSA 
consortium. Diagnoses were confirmed by expert hematopathologists. Criteria used to define 
TFH-like PTCL, NOS were previously reported 8. A subset of these patients were analysed for 
TET2, IDH2 and DNMT3A mutations in previous studies8,9 The study was approved by the local 
ethics committee (CPP Ile de France IX 08-009). 
WGS, WES and TDS 
Libraries were constructed for WGS following a standard protocol26. 100-bp paired-end reads 
were generated using an Illumina HiSeq 2000 Sequencer (version 3 chemistry). Reads were 
mapped to the NCBI Build 36.1 reference genome using the Burrows-Wheeler Aligner (BWA) 
alignment tool version 0.5.7, algorithm aln. PCR duplicates were eliminated using Picard version 
1.38. Indels and Single Nucleotide Variants (SNVs) were called using Strelka version 1.0.14, 
removing false positive calls internally. Variants were independently identified for each tumor-
VALLOIS et al.        Mutation-induced TCR activation in TFH nodal PTCL
8 
germline pair, using the germline as reference. GRCh37 coordinates of the filtered indels and 
SNVs were obtained using LiftOverVCF. Variants were annotated with VEP, and their read 
counts were obtained using in-house scripts. Copy Number Variations (CNVs) were identified 
using HMMcopy. Commonly deleted or amplified regions from WGS were visually identified 
using the Integrative Genome Viewer Software (IGV, https://www.broadinstitute.org/igv/). 
Deleted loci and genes having SNVs and/or CNVs in at least two patients are listed in Tables S3 
and S4. 
TDS of sixty-nine genes (Table S5) was performed on the extended cohort. Systematic 
sequencing errors were removed by adding two randomly selected blood samples from four 
healthy volunteers to each run. Libraries were prepared using the True-Seq Custom Amplicon kit 
(Illumina) and sequenced on a MiSeq machine (Illumina, 1000x mean depth, mean coverage 
94%). Variants were called using MiSeq reporter using default settings and were visually 
inspected on IGV. All synonymous variants and known SNPs with an allelic frequency above 
0.1% in public databases (dbSNP131, 1000 Genomes Project, 5000 Exomes project) were 
filtered out. We excluded variants found in normal samples, in ambiguously mapped regions 
from captured pseudogenes, and in regions of low complexity. Candidate variants were 
independently validated in a second round of TDS: we selectively amplified the amplicons 
covering the positions of candidate mutations (IonAmpliseq kit, Lifetechnologies) and sequenced 
them on a Ion PGM System (Lifetechnologies; 1305x mean depth, mean coverage 91.64%). 
Variants were called using default settings of the IonReporter software and reviewed with IGV. 
The final variants list (Table S6) was generated applying the following flitering criteria: a) 
variants called by both platforms, b) variants with minor allele frequency (MAF) < 0.4, c) 
variants already described as somatic in the COSMIC database. Filter b) was introduced to take 
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in to account the low tumor content and the inavaillability of matched normal samples. The 
threshold was defined based on the Minor Allelic Frequency (MAF) range of well-characterized 
AITL mutations, such as in RHOA and CD2812-14,25. Variants were annotated using GeneTalk 
(http://www.gene-talk.de/).
Cloning and Functional validation 
A detailed description is provided in supplemental material. Briefly,  we performed site-directed 
mutagenesis of RHOA, PLCG1 and CARD11 mutations on cloned cDNAs into pcMV6-MycFlag 
(RHOA, PLCG1) (Origene, C terminal tag) and pcDNA3-HA (CARD11) (N terminal tag)27 
vectors. RHOA variants were functionally assessed in vitro with rhotekin pull-down assays12-14 
and SRE (Serum Responsive Element) (Promega, Madison, WI, USA)  luciferase reporter assay 
using HEK293T cells 
PLCG1 and CARD11 variants were functionally tested by fluorescence resonance energy 
transfer (FRET)-based determination of their ability to induce MALT1 protease activity in 
HEK293T cells 28 and in luciferase-based assays using a NFAT reporter in HEK293T cells 
(forPLCG1) or a NF-B reporter in Jurkat cells deficient in CARD1129  (kindly provided by Dr. 
Xin Lin) (for CARD11) .  
Western blot analysis 
The following primary antibodies were used in Western blotting: anti-HA (Covalab 
Biotechnology), anti-Myc (clone 4A6, Millipore), anti-CARD11 (clone 1D12, Cell Signaling), 
anti-MALT1 28  and anti-Actin (ab3280, Abcam). Secondary antibodies were purchased from 
Jackson Laboratories. 
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Gene expression and enrichment analysis 
Gene expression profiles generated by hybridization on Affymetrix U133 Plus 2.0 were available 
for the extended cohort3.  Rotation testing using mean ranks (ROMER, R package limma) was 
used to determine the gene set signature enrichments in TCR_Mut compared to TCR_WT 
patients. A total of 304 signatures, including 23/50 hallmark signatures and nine signatures from 
the curated and immunogenic signature collection of the Molecular Signatures Database 
(MSigDB, http://software.broadinstitute.org/gsea/msigdb), all signatures of interest in lymphoid 
biology (Staudt, lymphochip.nih.gov/signaturedb/) and two manually annotated  sequences 
linked to TCR signaling, were tested. 
Clinical correlations and survival analysis 
Frequency differences of categorial variables were analyzed using Fisher’s exact test, while 
differences in continuous variables were tested with the Wilcoxon rank sum test. Overall survival 
(OS) was defined as time from diagnosis to death or last follow up, while progression free 
survival (PFS) was defined as time from treatment initiation to death or progression or last 
follow up. Analyses of OS and PFS were performed using the Kaplan-Meier method and hazard 
ratio differences were computed with the log rank test. 
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Results 
Whole exome/genome sequencing reveals alterations in T-cell signaling genes in AITL 
Eleven tumor samples from 10 AITL patients were subject to WGS or WES and compared to 
germline DNA (Figure S1 and Table S1). On average, 91% of the genome had >10× coverage, 
with 68% having >30×. A mean of 27 single nucleotide variations (SNV) per patient (range: 11-
50) was observed in coding regions, except in a sample from a relapsing patient with a
chromothripsis pattern of structural variation (Figure S2) and 225 SNVs. In one patient 
refractory to first-line therapy, WGS performed on tumor biopsies at diagnosis and after 5 cycles 
of chemotherapy, revealed a similar profile of alterations, with identical TET2 and ANKRD62 
SNVs in both samples. CNV analysis revealed multiple loci deleted in a number of patients, with 
eight minimal common regions (Table S3), mostly in three patients. A total of 39 genes had 
SNVs and/or CNVs in at least two patients (Table S4). Apart from RHOA G17V and TET2 
mutations, 9/39 (23%) altered genes were related to TCR (n=7), Toll-like receptor (n=1) or Wnt 
(n=1) signalings. Other mutations were found in genes involved in the cell cycle (n=5), 
autophagy (n=2), or other pathways (n=6). Six additional genes relevant to TCR or JAK/STAT 
signaling (CTNNB1, VAV1, MTOR, CREBBP, PIK3C2G, JAK1) were altered in one patient each.  
Collectively, T-cell signaling alterations were found in 7/10 patients.  
Frequent mutations of RHOA and other TCR-related genes are confirmed in an extended 
cohort of TFH-derived lymphomas 
We designed a panel of 69 genes for TDS, partly based on findings in the discovery cohort 
(Tables S5 and Figure S1), for application on our extended cohort (Table S2). After orthogonal 
cross-validation and conservative filtering (Table S6 and Figure S3) we validated 70 variants in 
29 genes (Figure 1), including missenses (61), frameshifts (5), non-frameshift deletions (2), and 
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stop-gain mutations (2). Mutations were detected in 70/85 samples (82%, mean mutations per 
sample = 1.8). RHOA and other TCR signaling-related genes accounted for 19 of 29 (65.5%) 
mutated genes (Figures 1 and 2). 
RHOA mutations include a novel activating K18N variant 
RHOA was the most frequently mutated gene among those analyzed (51/85; 60% patients), with 
a similar prevalence in AITL and TFH-like PTCL. Consistent with previous reports12,13, the 
G17V variant was found in most of the cases. We also identified a novel K18N mutation (VF: 
[5.5%; 7.4%; 10%]) in three AITL patients (Figure 3A and Table 1). Both mutations occur in 
the highly conserved GTP binding site of RHOA. We tested Myc-tagged G14V (constitutively 
active30), G17V (dominant negative), K18N as well as WT RHOA in a pull-down assay using 
Rhotekin-RBD (Rho Binding Domain) beads (Figure 3B). While RHOA G17V already 
characterized as dominant negative12-14 did not bind RBD beads even in the presence of FBS as 
compared to WT, RHOA K18N showed a marked increase of RBD beads binding similarly to 
RHOA G14V (Figure 3B). Moreover, unlike RHOA G17V that did not activate and even 
repressed transcription from the SRE under serum activation, RHOA K18N markedly enhanced 
its transcription (Figure 3C).  
Mutations in other TCR signaling-related genes are variably recurrent and diverse 
Apart from RHOA, mutations in genes involved in TCR costimulation or signaling were 
detected in 42/85 patients (49%) (Figures 1-2 and Table 1).  
CD28 and TCR-proximal signaling genes 
Three different CD28 mutations, T195P, D124V and D124E, all described previously13,25,31 were 
identified in 4, 2 and 2 AITL patients, respectively (8/85, 9.4%) (Figure 4A). All TFH-like 
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PTCL were CD28-WT. T195P and D124V mutations are known to enhance TCR/CD28-induced 
NF-kB activity in vitro 25,31. Three patients (2 AITL, 1 TFH-like PTCL; 3.5%) harbored 
mutations in FYN, a TCR- and CD28-proximal kinase component (Figure 4B). Mutations in the 
SH2 domain (S186L) and the absence of phosphorylated tyrosine 531 (T524fs or Q527X 
mutations) probably confer enhanced kinase activity by disrupting their inhibitory interaction 12. 
The two amino acid substitution in the tyrosine kinase domain of LCK observed in one AITL 
patient is expected to enhance its kinase activity 32. We did not find mutations in ICOS, ZAP70, 
LAT or ITK. 
NF-kappaB/NFAT pathway 
Ten different missense mutations spanning the coding region of PLCG1 (VF: [2.1%; 38%]) were 
identified in 12/85 patients (8 AITL, 4 TFH-like PTCL; 14.1%) (Figure 5A).  Apart from 
previously reported variants in Adult T-cell Leukemia/Lymphoma (ATLL) or in other PTCL20-24, 
we identified two novel variants (E730K and G869E). We generated all mutant constructs and 
tested their activity against WT PLCG1 in a FRET-based reporter assay of MALT1 protease 
activity27,28 (Figure 5B) and in a NFAT luciferase reporter assay (Figure 5C). Both experiments 
confirmed that the S345F and S520F variants were activating 21. All six variants in the PI-PLC, 
SH2, SH3 and C2 domains were also activating, increasing the FRET signal by 1.7 to 3-fold and 
the luciferase expression by 4 to 5-fold. Of the two PH1 domain variants, R48W had no effect in 
both assays, while E47K increased NFAT reporter activity by 2.1 fold and FRET signal by 1.5-
fold. 
Point mutations in CARD11, which encodes a scaffolding protein downstream of PLCG1 
required for CD28/TCR-induced NF-kB activation 28 were found in two AITL and one TFH-like 
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PTCL (3.5%). The F176C variant affects the coiled-coil domain of the protein, commonly 
mutated in DLBCL 33. The S547T and F902C variants map to linker regions with undefined 
structure (Figure 5D). In a FRET-based assay28, F176C and S547T enhanced MALT1 
proteolytic activity by 2- and 4-fold, respectively, while  the F902C mutant, previously reported 
in ATLL patients 20, had no detectable effect (Figure 5E). When transfected into Jurkat cells 
deficient for CARD1129, we found that, compared to wildtype CARD11, all three variants 
induced enhanced NF-kB reporter activity in response to PMA/Ionomycin stimulation (Figure 
5F).  
PI3K pathway 
Six patients (3 AITL, 3 TFH-like PTCL; 7%) showed mutations in PI3K genes encoding the 
regulatory subunits PIK3R1 (n=5), PIK3R5 (n=1) or the catalytic subunit PIK3CA (n=1) (Figure 
4C-E). These mutations likely enhance the catalytic subunit activity or increase PIK3R1 binding 
to CD28 34. Five AITL patients (5.9%) had mutations in PDPK1 (PDK1), a master 
serine/threonine kinase with multiple targets including AKT. Three missense mutations were 
found on or near its kinase domain, suggesting an activating effect35 (Figure 4F).  Four different 
CTNNB1 mutations, known to occur in a variety of carcinomas and Wilms tumors, were 
identified in five patients (4 AITL, 1 TFH-like PTCL; 5.9%) (Figure 4G). All have been 
previously characterized as activating or stabilizing variants that induce persistent signaling and 
increased proliferation, and have been linked to both poor treatment response and frequent tumor 
relapse in various tumors36,37. 
AP-1/MAPK pathway 
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Eleven patients (8 AITL, 3 TFH-like PTCL; 13%) had mutually exclusive activating mutations 
in the MAPK pathway, which regulate the activity of the AP-1 transcription factor family. 
Activating KRAS 38 and STAT326,39  mutations were detected in three and two patients each 
(Figure 4H). We also found five missense mutations in GTF2I (TFII-I) 40, (Figure 4I) that are 
likely activating, as those reported in thymic epithelial tumors 41. 
GTPases pathway 
Apart from highly recurrent RHOA mutations, four patients (3 AITL, 1 TFH-like PTCL; 4.7%) 
harbored previously undescribed frameshift deletions or missense mutations in VAV1, a 
guanosine exchange factor for RAC1, CDC42 and RHOA (Figure 4J). Two missense mutations 
were on the second SH3 domain, where a D797 residue mutation was previously shown to 
activate VAV1-mediated transformation via cell-cell contact deregulation 42. 
Analysis of sequential biopsies 
Analysis of paired samples in four refractory or relapsed patients (Table S8) showed that the 
mutations identified at diagnosis were also present in the second biopsy, with overall very 
similar VF. Within the limit of the panel of genes examined, two patients presented one 
additional mutation at relapse (CTNNB1 and VAV1), at somewhat lower VF than those present at 
diagnosis. Although this analysis is limited to a few pairs of samples, it indicates that the 
mutational heterogeneity that characterizes many AITL samples appears to be preserved and 
essentially not modified by the treatments administered. 
Activating mutations in TCR signaling-related genes correlate with molecular signatures 
reflecting higher T-cell activation and with response to therapy 
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A total of 66/85 patients harbored mutations in TCR signaling genes. To assess the biological 
and clinical impact of the tumor mutational status, we focused on patients with mutations in TCR 
signaling-related genes other than RHOA, designated hereafter as “TCR_Mut” (42/85 cases, 
49%), and compared them to those with only RHOA, or no detectable mutation, designated 
“TCR_WT” (43/85 cases, 51%). (Figure 6).  
Mutations in TCR-related genes other than RHOA were virtually non-overlapping, and 
the vast majority (47/56 distinct variants, 84%) were either functionally validated (n=24) or 
predicted (n=23) to be biologically gain-of-function mutants (Figure 6). Consequently, nearly all 
TCR_Mut patients (39/42 patients, 93%) harbored at least one activating mutation.  
There was no significantly differentially expressed genes between TCR_Mut and 
TCR_WT samples (Figure S4). However, the molecular signatures of TCR_Mut were 
significantly enriched in fifteen gene sets compared to TCR_WT by enrichment analysis (Figure 
7A, Table S7, Figure S5), reflecting the activation of signaling pathways like PI3K, NF-kB17, 
IRF4, JAK-STAT, as well as the upregulationof calcium signaling target genes. This points 
towards TCR signaling activation in TCR_Mut PTCLs. TCR_Mut samples also showed 
enrichment in cell cycle signatures reflecting increased proliferative activity. Finally, there was a 
trend for TCR_Mut samples to have downregulated proximal TCR signaling genes (signature 
“T_cell”) such as TCR (TCRα, TCRβ; CD3δ, CD3γ),  signaling molecules (LAT, TRIM, SAP, 
FYB, ZAP70) and cell surface markers (adjusted p. value = 0.10), a feature consistent with 
sustained T-cell activation 43. 
Then, when comparing the clinical features and outcome of TCR_Mut and TCR_WT 
patients, no significant differences in main clinical characteristics at presentation (Table S9) or 
in overall survival (18 vs 40 months median OS; 5 year OS 20% vs 29%; p=0.37) were found 
(Figure S6). Strikingly, however, among the 59 patients (49 AITL and 10 TFH-like PTCLs) who 
received anthracyclin-based induction chemotherapy, 11/33 (33%) TCR_Mut patients versus 
2/26 (8%) TCR_WT (p=0.02, Table S9) showed early progression, relapse or no response to 
treatment within the first six months after diagnosis. This, however, did not translate into a 
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statistically significant difference in progression-freee survival at 5 years (21% versus 24% for 
TCR_Mut versus TCR_WT patients, p=0.15) (Figure 7B-C).  
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Discussion 
In this study, we confirmed the high prevalence of RHOA mutations in TFH-derived PTCL, with 
most samples bearing the dominant negative G17V variant. Interestingly, we identified a new 
K18N variant in 3% of the patients that presented activating features in in vitro assays. This 
intriguing finding of distinct RHOA mutations with apparently opposite functional properties in 
the same disease, was also recently documented  in ATLL44,45. Further studies are warranted to 
understand how these variants may contribute to the pathogenesis of PTCLs.  
Apart from RHOA alterations, we identified activating and virtually mutually exclusive 
mutations in diverse TCR signaling genes in half of TFH-derived lymphomas. Individually, the 
frequencies of these mutations were variable, with the five most mutated genes (PLCG1, CD28, 
PIK3 elements, GTF2I, CTNNB1) being altered in 14% to 5% of the patients. CD28 and FYN 
mutations in AITL were previously described in a small number of cases12-14. Our study 
significantly expands these previous results, and strongly supports a role of activated TCR 
signaling in the pathogenesis of TFH-derived PTCLs, drawing strong parallels with the role of 
BCR signaling in B-cell lymphomas.  
Mutations in genes related to TCR co-stimulation and signaling were recently reported in 
other PTCL enties, like cutaneous T-cell lymphomas (CTCL), PTCL-NOS and ATLL20-24,46. 
Nonetheless, mutations in specific genes are variably recurrent in distinct entites 24,25, and for a 
given gene the distribution of the mutations and their relative prevalence are heterogeneous. For 
instance, PLCG1 and CARD11 mutations are highly prevalent (up to 18% and 15% of the cases, 
respectively) in CTCL, in which conversely CD28 mutations are not found. 20 CARD11 
mutations are more frequent in ATLL (24%) and Sésary syndrome (SS, 10.9%) than in this 
series of TFH-derived lymphomas. Whether the observed mutations are sufficient to induce 
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constitutive activation of the respective pathways, and how their effect may be dependent or 
influenced by antigen-driven or other stimulatory signals remains unknown. Interestingly, some 
of the TCR-related genes may be altered through point mutations or small indels as well as by 
major structural rearrangements, amplifications and deletions20,23,24. Collectively, these findings 
strongly suggest that genetic alterations impacting TCR signaling operate as a common 
pathogenic mechanism in several PTCL entities.  
Our analysis also explored the JAK/STAT and TLR pathways. Mutation-induced activation 
of the JAK/STAT pathway, highly prevalent in myeloid neoplasms, was recently identified as a 
major oncogenic mechanism in several T-cell leukemias and lymphomas derived from innate 
immune cells20,46-53. Our results suggest, however, that JAK/STAT mutations do not have the 
same importance in the pathogenesis of TFH-derived lymphomas, as only 4/85 patients bore a 
single activating mutation each in JAK1, JAK2, JAK3 or MYD88 (Table 1)54. Except for JAK2 
V617F, the three others were observed in PLCG1-mutated cases. 
Our data further support that AITL and TFH-like PTCL are closely related at the molecular 
level5, and share common oncogenic mechanisms. We and others have reported the occurrence 
of TET2, DNMT3A and RHOA mutations in a large proportion of both AITL and TFH-like PTCL 
patients5,8,9,12-14. This study extends the molecular overlap across TFH-derived neoplasms to 
genetic alterations in various TCR-signaling. Interestingly, CD28 mutations were exclusively 
identified in AITL patients, consistent with recent reports25,31. Similarly, IDH2 mutations were 
rarely detected in PTCL cases9,55, suggesting that the distribution of some genetic features might 
be relevant in distinguishing AITL from other TFH-derived nodal lymphomas, which otherwise 
share many common features5.  
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In the proposed multistep model of pathogenesis for TFH-derived PTCL, mutation-induced 
epigenetic deregulation, possibly arising in early hematopoietic precursors, may promote the 
emergence of premalignant cells, which requires additional genetic events to acquire a 
definitively malignant phenotype13,56. It has been thus suggested that RHOA alterations occur as 
a second event in TET2 and/or DNMT3A-mutated cells13,56,57. The prevalence of mutations in 
TET2, DNMT3A and IDH2 analyzed in a subset of our cases was 52% (34/65 cases), 29% (17/56 
cases) and 30% (21/71 cases), respectively8,9. These mutations were not mutually exclusive, and 
in fact tended to co-occur with each other, as previously reported 12,13. We also found a tendency 
for RHOA mutations to associate with epigenetic alterations, since RHOA mutations were 
detected in 31/41 (76%) cases mutated in TET2, DNMT3A and/or IDH2, but in only 8/23 (35%) 
cases without epigenetic mutations (p=0.003). Since the proportion of neoplastic cells in AITL is 
typically low and variable from case to case3, the comparison of VF of different mutated genes 
was performed for each individual sample. In 13 cases harboring mutations in both TET2 and/or 
DNMT3, and RHOA or IDH2 with available VF, the TET2/DNMT3A VF was significantly higher 
than for RHOA or IDH2 (Figure S7A). There was no obvious association  of RHOA mutations 
with other TCR-related genes, as 27/51 (53%) RHOA-mutated and 15/34 (44%) RHOA-WT 
cases were mutated in other TCR-related genes (p=0.51). In twenty-seven cases mutated in both 
RHOA and one or several genes of the TCR, JAK/STAT or TLR pathways, no significant 
difference in VF means was observed between RHOA and other genes (Figure S7B). 
Although our results warrant confirmation in cohorts of patients treated on prospective 
clinical trials, they suggest that the mutational status of TCR-related genes may have important 
clinical implications, predicting early treatment failure with anthracyclin-based chemotherapy in 
TFH-related PTCL patients. Importantly, several activating mutations found in PI3K or NFkB 
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pathways could be targeted by idelalisib or the proteasome inhibitor bortezomib, respectively. It 
is of interest to determine their efficacy in TCR_Mut patients12,21, possibly in combination with 
demethylating agents58. Thus, similar to the importance of targeting BCR signaling in B-cell 
lymphomas with the BTK inhibitor ibrutinib17, characterization of the TCR mutational status 
might open new avenues to design specific and hopefully more effective therapies. In clinical 
practice, given the high number of genes involved and the diversity of mutations found, targeted 
deep sequencing with high depth/coverage appears as the method of choice for selecting patients. 
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Tables Legends 
Table 1. Characteristics of the 70 variants identified by Targeted Deep Sequencing of TCR, 
JAK/STAT and TLR-related genes in 85 TFH-derived PTCL samples. Genes are organized 
by functional groups. 
Figures Legends 
Figure 1. Mutational landscape of nodal TFH-derived lymphomas. The results of targeted 
deep sequencing of 69 genes in 72 AITL (light grey) and 13 TFH-like PTCL (dark grey) are 
presented. Ten cases (8 AITL and 2 TFH-like PTCL) with no mutations detected are not 
represented. TET2, DNMT3A and IDH2 mutations available for a subset of the cases reported in 
previous studies 8,9 are also shown. Case-mutation pairs for which data are not available are 
indicated by a 0. Mutated genes (rows) are arranged by decreasing order of mutation frequency. 
Patients (columns) are arranged from left to right based on their mutational status following gene 
ranking. 
Figure 2. Mutations of TCR signaling-related genes in nodal lymphomas of TFH origin.  
The intracellular pathways following TCR ligation and costimulatory activation were 
reconstructed using the Ingenuity pathway analysis (IPA) tools, the KEGG database and other 
references.  Four main pathways are individualized, from left to right: (1) PI3K pathway 
following CD28/TCR-dependent FYN phosphorylation and ultimately resulting in CTNNB1 
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translocation into the nucleus; (2) NF-kB/NFAT pathway proximally initiated by ITK-dependent 
PLCG1 activation and resulting in NFAT1, NF-kB and IRF4 activation; (3) AP-1/MAPK 
pathway that comprises  ITK-dependent GTF2I activation, MALT1-induced JNKs activation and 
PLCG1- GRB2/SOS-induced MAPK components activation; and (4) GTPase-dependent 
pathway, including RHOA, responsible for cytoskeleton remodelling upon co-stimulatory/TCR 
activation. The main positive interactions are indicated by solid green arrows, while inhibitory 
effects are indicated in red.  The TCR signaling elements are depicted in yellow or red if the 
coding genes were mutated in <5% or 5% or more cases, respectively. The most frequently 
mutated genes (PLCG1, CD28, PI3K components, CTNNB1 and GTF2I) were part of 
costimulatory, NF-kB/NFAT, PI3K and AP-1/MAPK intracellular signaling pathways. Proteins 
corresponding to wild type genes are indicated in blue, while genes that were not sequenced are 
in grey. ERK1, ERK2, JNK1, JNK2 and PDK1 are protein names for MAPK1, MAPK3, MAPK8, 
MAPK9 and PDPK1 genes respectively. 
Figure 3. RHOA mutations in AITL and TFH-like PTCL. (A) Overview of the RHOA 
protein structure, showing G17V (42 AITL, 6 TFH-like PTCL) and the novel K18N (3 AITL) 
variants which target the highly conserved GTP/GDP binding site of RHOA. (B) Protein blot 
analysis of GTP-bound RHOA-Myc in rhotekin pulldown assay from HEK293T cells expressing 
indicated RHOA constructs. IP: immunoprecipitation. Representative of six independent 
experiments. (C) SRE (Serum Responsive Element) luciferase reporter assay monitoring the 
activity of RHOA K18N mutant, compared with WT, G14V or G17V mutants, previously 
characterized as activating and dominant negative respectively. Cells were stimulated (light grey) 
or not (dark grey) with FBS during 6 hours. Data are represented as mean ± sem (standard error 
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on mean) from four independent experiments. Significant differences in activation activity were 
determend using two-way ANOVA with repeated measurement (**, p≤0.01; ***, p≤0.001 
compared to WT). (D) Representative western blot from a luciferase assay experiment. Ectopic 
myc tagged RHOA expression is revealed by anti-Myc. Anti-Actin blotting serves as loading 
control. 
Figure 4. Mapping of variants in TCR signalling genes mutated in at least 3 patients. (A) 
CD28: the D124V/E variants involve the extracellular part of the receptor, while T195P lies in 
the intracellular, C-terminal domain, between the two domains allowing interaction with PIK3R1 
(YVKM sequencce) or GRB2/VAV (PRRP sequence) proteins (B) FYN: the five mutations 
indicated occurred in three patients; one patient harboured two mutations (a); two mutations in 
adjacent positions in the SH3 domain (b) were observed on the same allele in another patient. 
(C-E) PI3K subunits: when appropriate cellular stimuli are present, the nSH2 and cSH2 domains 
of PIK3R1 bind phosphorylated tyrosines (YXXM motif) in activated receptors (CD28) and 
adapter proteins, thereby activating the PIK3CA (p110a) catalytic subunit without releasing the 
PIK3R1 (p85a) interaction with p110a through their iSH2 and ABD domains respectively. The 
K141R missense affects the Rho-GAP domain, while iSH2 and the second SH2 domains of 
PIK3R1 bore two missenses each (Q475P, T576A and G680S, V704M respectively). The 
A259V mutation, described as somatic in COSMIC, affects a linker region of PIK3R5. Finally, 
the L1001P point mutation affects the PIK3CA kinase domain. (F) PDK1: one inframe INDEL, 
one frameshift INDEL and three missense affect PDK1 protein. (G) CTNNB1: three previously 
described activating missenses affect the GSK3β inhibitory domain (exon 3), while the K335T 
activating mutation affects the armadillo repeats region (H) KRAS: three missense mutations 
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alter two N-terminal nucleotide binding regions. (I) GTF2I: five missense mutations affect the 
GTF2I transcription factor, among which two are found in different GTF2I-like domains. (J) 
VAV1: two frameshift deletion and two missenses affect VAV1, three being localized in the C-
terminal SH3 domain of the protein.  In all figure panels, previously described activating 
mutations are in green boldface, while mutations previously described but not functionally tested 
are underlined. PDK1 is the protein name of PDPK1 gene. 
Figure 5. Mapping and functional analysis of PLCG1 variants and CARD11 variants. (A) 
Schematic representation of PLCG1 protein with mapping of the 10 missense mutations 
identified in AITL (circles) or TFH-like PTCL (squares) cases. Previously described activating 
mutations are in green boldface and mutations previously described but not functionally tested 
are underlined. (B) Monitoring of PLCG1-mediated MALT1 activation via a FRET-based 
reporter assay. Data are represented as mean ± sem (standard error on mean) from three 
independent experiments. Significant differences in activation activity were determined using 
one-way ANOVA (**, p≤0.01; ***, p≤0.001). Representative western blot from a MALT1 
activation experiment. PLCG1 expression is revealed by anti-Myc tag blotting while MALT1 
expression is shown by anti-MALT1 antibody. (C) NFAT luciferase reporter assay monitoring 
activity of PLCG1 mutants, compared with previously-reported activating mutants (green). Data 
are represented as mean ± sem (standard error on mean). from seven independent experiments. 
Significant differences in activation activity were determend using one-way ANOVA (*, p≤0.05; 
**, p≤0.01). Representative western blot from a luciferase assay experiment. Ectopic myc tagged 
PLCG1 expression is revealed by anti-Myc. Anti-Actin blotting serves as loading control. (D) 
Schematic representation of CARD11 protein with mapping of the three point mutations found in 
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two AITL (circles) and one TFH-like PTCL-NOS (square) patients. A previously-described 
mutation is underlined. (E) Monitoring of CARD11-mediated MALT1 activation via a FRET-
based reporter assay. Data are represented as mean ± sem (standard error on mean) from six 
independent experiments. Significant differences in activation activity were determined using 
one-way ANOVA (*, p≤0.05; **, p≤0.01). The known activating L244P variant (green) was 
used as a positive control for the experiment. Representative western blot from a MALT1 
activation experiment. CARD11 expression is revealed by anti-HA tag blotting while MALT1 
expression is shown by anti-MALT1 antibody. (F) NF-KB luciferase reporter assay in Jurkat 
cells deficient for CARD11 monitoring activity of CARD11 mutants, compared with previously-
reported activating mutants (green). Data are represented as mean ± sem from four independent 
experiments. Significant differences in activation activity were determined using two-way 
ANOVA (*, p≤0.05; **, p≤0.01; ***, p≤0.001 compared to WT PMA/IONO). 
Figure 6. Mutual exclusivity of TCR signaling variants. The mutational status of TCR-related 
genes is represented for the 85 patients of the extended cohort. Genes other than RHOA are 
ranked by decreasing mutation frequency, and show an essentially mutually exclusive mutation 
pattern. In total, 49% of cases were mutated in one or several TCR-related gene(s) other than 
RHOA (hereafter considered as TCR_Mut), 28.5% were mutated in RHOA only and  22.5% 
harbored no mutation in any of the genes tested (collectively considered as TCR_WT). 
Figure 7. Biological significance and clinical relevance of TCR signaling-related mutations 
(A) Spider plot representation of gene sets differentially enriched in patients with or without 
mutations in genes related to TCR signaling (TCR_Mut versus TCR_WT). Genes tested in the 
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enrichment analysis were selected from signatures relevant in T- and B-cell differentiation and 
activation. Statistical significance of the enrichment was reached for gene sets 1 to 15 (p<0.05); 
for gene set 16, marginal significance was observed (p=0.1). (B, C) Overall survival (OS, B) and 
progression-free survival (PFS, C) of patients with (red) or without (blue) mutations in TCR 
signaling-related genes. Analyses are restricted to the 59 patients treated with anthracyclin-based 
chemotherapy. Mutated patients show a trend toward a shorter PFS (11 vs 36 months) than WT 
patients (p= 0.15).  
VALLOIS et al.        Mutation-induced TCR activation in TFH nodal PTCL
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Functional Groups GENE Amino Acid Change Mutation type Domain New/reported Effect References
CD28 D124V missense extracellular AITL, ATLL gain of function (F) 20, 25
CD28 D124E missense extracellular AITL, ATLL gain of function (F) 20, 25
CD28 T195P missense cytoplasmic AITL, ATLL gain of function (F) 20, 25, 31
LCK b;N446K missense kinase new probably gain of function (P)
LCK b;P447R missense kinase new probably gain of function (P)
FYN Q527X stop gain ATLL probably gain of function (P) 20
FYN a;525_525del frameshift deletion new probably gain of function (P)
FYN a;S186L missense SH2 new probably gain of function (P)
FYN b;
 K108fs frameshift deletion new probably loss of function (P)
FYN b;
 E107S missense SH3 new probably loss of function (P)
PLCG1 E47K missense PH 1 ATLL gain of function (F) 20
PLCG1 R48W missense PH 1 ATLL, SS no effect (F) 20, 24
PLCG1 D342G missense PI-PLC X-box ATLL, MF gain of function (F) 20
PLCG1 a;
 S345F missense PI-PLC X-box AITL, MF, SS, ATLL gain of function (F) 20, 21, 22, 24
PLCG1 a;
 S520F missense PH 2; first part MF, SS, ATLL gain of function (F) 20, 21, 24
PLCG1 E730K missense SH2 2 new gain of function (F)
PLCG1 G869E missense near SH3 new gain of function (F)
PLCG1 E1163K missense C2 ATLL, SS gain of function (F) 20, 24
PLCG1 D1165H missense C2 ATLL, SS gain of function (F) 20, 24
PLCG1 D1165G missense C2 ATLL gain of function (F) 20
CARD11 F902C missense ATLL gain of function (F) 20
CARD11 S547T missense new gain of function (F)
CARD11 F176C missense coiled coil new gain of function (F)
TRAF6 Q347X stop gain coiled coil /MATH new NA
PIK3R1 K141R missense RHO-GAP new probably gain of function (P)
PIK3R1 Q475P missense iSH2 new probably gain of function (P)
PIK3R1 T576A missense iSH2 new probably gain of function (P)
PIK3R1 G680S missense SH2 2 new probably gain of function (P)
PIK3R1 V704M missense SH2 2 new probably gain of function (P)
PIK3R5 A259V missense carcinoma (liver) probably gain of function (P) 34
PIK3CA L1001P missense PI3K/PI4K new probably gain of function (P)
PDPK1 19_20del inframe deletion new NA
PDPK1 151_152del frameshift deletion protein kinase new probably loss of function (P)
PDPK1 R324Q missense protein kinase new probably gain of function (P)
PDPK1 P340Q missense protein kinase new probably gain of function (P)
AKT1 G294R missense protein kinase new probably gain of function (P)
CTNNB1 a;
 T41A missense Phospho by GSK3b
hepatocellular carcinoma, 
acute lymphoblastic leukaemia, 
breast cancer, wilms tumor
gain of function (F) 36
CTNNB1 H36P missense
hepatocellular carcinoma, 
acute lymphoblastic leukaemia, 
breast cancer, wilms tumor
gain of function (F) 36
CTNNB1 a;
 S45F missense
hepatocellular carcinoma, 
acute lymphoblastic leukaemia, 
breast cancer, wilms tumor
gain of function (F) 36
CTNNB1 K335T missense hepatocellular carcinoma gain of function (F) 37
KRAS I36M missense haematopoeitic neoplasms gain of function (F) 38
KRAS A18D missense GTP binding lymphoma gain of function (F) 38
KRAS G13D missense GTP binding solid tumors gain of function (F) 38
MAPK3 R278Q missense protein kinase new probably gain of function (P)
STAT3 E616G missense SH2 lymphoma gain of function (F) 26, 39
STAT3 E616K missense SH2 lymphoma gain of function (F) 26, 39
GTF2I D317E missense new probably gain of function (P)
GTF2I N340S missense new probably gain of function (P)
GTF2I R523S missense GTF2I-like new probably gain of function (P)
GTF2I L607F missense GTF2I-like new probably gain of function (P)
GTF2I R702Q missense new probably gain of function (P)
RHOA K18N missense GTP binding new gain of function (F)
RHOA G17V missense GTP binding AITL, ATLL dominant negative (F) 12, 13, 14, 20, 44
VAV1 151_158del frameshift deletion new probably loss of function (P)
VAV1 778_783del frameshift deletion new NA
VAV1 D797G missense SH3 2 new probably gain of function (P)
VAV1 Y826S missense SH3 2 new probably gain of function (P)
VAV2 Y214C missense DH gastric carcinoma probably dominant negative (P)
JAK1 D831E missense kinase new probably gain of function (P)
JAK2 V617F missense myeloproliferative disorders gain of function (F) 47-53
JAK3 A699V missense kinase lymphoma, carcinoma gain of function (F) 47-53
MYD88 S219C missense TIR DLBCL, lymphocytic leukaemia probably gain of function (P) 54
Table 1. Characteristics of the 70 variants identified by Targeted Deep Sequencing of TCR, JAK/STAT and TLR-related genes in 85 TFH-derived PTCL samples. Genes are organized by 
functional groups.
JAK/STAT and TLR 
pathways
AITL: angioimmunoblastic T-cell lymphoma, ATLL: adult T-cell lymphoma/leukemia, SS: Sezary syndrome, MF: Mycosis Fungoides, DLBCL: diffuse large B-cell lymphoma 
a:
 gene variants found in the same patient but in different alleles
b:
 gene variants found in the same patient and in the same allele
F: Functional validation; P: literature and models based
co-stimulatory and 
proximal TCR 
signalling
PI3K pathway
GTPases pathway
NF-kB/NF-AT pathway
AP-1/MAPK pathway
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Supplementary methods 
RHOA Pull-down assay 
2x10
6
 HEK293T cells were lipofected 24 h after seeding in 10 cm dishes with 20 µg of indicated
constructs. Twenty-four hours later, cells were serum-starved for another 24h period. Then, cells 
were harvested or serum-stimulated during 20 minutes. Serum-starved and serum-stimulated 
cells were washed once with ice-cold PBS and lysed in IP buffer (50 mM Tris, 10 mM MgCl2, 
0.3 M NaCl, 2% IGEPAL, 1mM PMSF, Protease Inhibitor Cocktail 1X (Roche) and Phosphatase 
Inhibitor Cocktail 1X (Roche)). After clearing of lysates by centrifugation, protein content was 
quantified using the Precision Red advanced Protein Assay (Cytoskeleton). Next, lysates 
containing 200 µg of protein were incubated with 40 µL of Rhotekin-RBD beads (Cytoskeleton) 
for one hour at 4°C with rotation. After incubation, beads were washed twice in ice-cold wash 
buffer (25 mM Tris, pH 7.5, 30 mM MgCl2 and 40 mM NaCl) and resuspended with 30 µL of 2x 
Laemmli buffer. The presence of Myc-tagged activated RHOA associated with Rhotekin-RBD 
beads was determined by immunoblotting with an anti-Myc antibody (Millipore). 
Luciferase-based activity assays 
The analysis of the activity of RHOA, PLCG1 and CARD11 mutants was performed using SRE 
(Serum Responsive Element; Promega, Madison, WI, USA), NFAT (Addgene, Cambridge, MA, 
USA) and NF-kB (Promega, Madison, WI, USA) luciferase-based reporter systems, respectively. 
For RHOA and PLCG1: 50’000 HEK293T cells/well were lipofected (Lipofectamin 2000, 
Lifetechnologies, Carlsbad, CA, USA) 24h after seeding with 10 ng of Renilla luciferase vector, 
400 ng of the Firefly luciferase reporter and 300 ng of PLCG1 or RHOA constructs. Twenty-four 
hours later, Firefly and Renilla luciferase activities were measured using the Dual-Luciferase 
Reporter Assay System from Promega according to manufacturer’s instructions (Promega, 
Madison, WI, USA). 
For CARD11: 10x10
6
 Jurkat cells deficient for CARD11
29
 (kindly provided by Dr. Xin Lin) were
electroporated (BioRad, Hercules, California, USA) with 200 ng of Renilla luciferase vector, 5 
µg of the NF-kB  (Promega, Madison, WI, USA) Firefly luciferase reporter, 5 µg of a Large T 
expressing plasmid and 10 µg of CARD11 constructs. Fourty-eight hours later, Firefly and 
Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System 
from Promega according to manufacturer’s instructions (Promega, Madison, WI, USA). 
FRET (Fluorescence Resonance Energy Transfer)-based MALT1 activity assays 
FRET-based reporter assays were performed to assess CARD11 and PLCG1-dependent MALT1 
protease activation in HEK293T cells as previously described
28. 85’000 HEK293T cells were
transfected with the eYFP–Leu-Val-Ser-Arg–eCFP reporter construct (which served as a 
MALT1 substrate), together with combinations of CARD11 or PLCG1 variants and MALT1 and 
BCL10 expression constructs. Twenty-four hours after transfection, cells were washed and 
resuspended in flow cytometry buffer (2% FCS in PBS) and analyzed with an LSR II flow 
cytometer (BD Biosciences) containing 405-, 488-, 561- and 640-nm lasers. To measure the 
eCFP and FRET signals, the transfected cells were excited with a standard 450/50 filter for 
collection of the eCFP fluorescence and a 585/42 filter for FRET fluorescence, respectively, and 
for each sample at least 5’000 highly eYFP+ cells were counted. Significant differences in 
activation activity were determined using one-way ANOVA (**, p≤0.01; ***, p≤0.001) Analysis 
was performed using a Repeated measures one-way ANOVA test with Dunett correction for 
multiple comparisons. 
Supplemental Figures 
Figure S1: Study workflow. 
WGS and WES of 11 paired normal and tumor samples from 10 AITL patients were used to 
screen for genes altered in at least two cases (SNV and/or CNV) or altered in one patient but 
relevant to TCR signaling or T-cell biology.  A panel of 69 candidate genes, including 45 related 
to TCR and 7 related to T-cell biology signaling, were selected for deep sequencing in an 
extended cohort comprised of 72 AITL and 13 TFH-like PTCL-NOS tumor samples at diagnosis. 
Integrated analysis of the mutational status together with clinical information and gene 
expression profiles (GEP; 65 AITL and 12 TFH-like PTCL, NOS) was performed to assess the 
clinical and biological relevance of the detected variants. 
Figure S2: Chromosomal rearrangements from patient with chromotripsis pattern.  
In one patient, a striking number of structural variation (SV) breakpoints and SNVs were 
detected in the tumor genome. 116 of these breakpoints could be attributed to an apparent 
chromothripsis event owing to linkages between these and a restricted set of loci in the genome. 
In the inset (upper left), the four affected chromosomes are shown with the individual intra- and 
interchromosomal rearrangements represented as arcs. Expansion of the regions containing 
breakpoints shows the full scope of SVs involved in this event. Of note, breaks affected introns 
or exons of a total of seven genes with the approximate coordinates of the genes indicated with 
gene symbols. The chromosome with the most SV breakpoints was 8, and many of these affected 
the TOX gene. This gene encodes a protein with a high mobility group (HMG) DNA binding 
domain thought to play a role in T-cell development. Structural alterations (including 
homozygous deletions) affecting TOX have recently been found to be common in primary 
central nervous system lymphomas. 
Figure S3: Variants frequencies distribution. 
The 103 variants were found in 45 out of 69 deep-sequenced candidate genes in 85 AITL or TFH-like PTCL-NOS patients are 
represented.  Variant frequencies (VF) were plotted for each patient. A VF threshold of 0.4 (red dotted line, chosen based on the 
maximum VF of RHOA and CD28 variants) was used to discriminate potential somatic from germline variants. Variants with VF 
above 0.4 but previously described somatic and/or with functional relevance (CARD11) (brown dots) were not filtered out. A total of 
70 variants were kept for further analysis. TET2, DNMT3A and IDH2 results are from a previous study (19 patients sequenced on 
PGM platform are shown).  
Figure S4: Principal component analysis (PCA) of AITLs and TFH-like PTCL-NOS 
coloured based on TCR pathway mutation status.  
PCA of GEP from TCR_Mut and TCR_WT patients indicate that the main sources of variability 
in AITL and TFH-like PTCL-NOS groups are not principally linked to TCR status; 
heterogeneity within AITL and TFH-like PTCL-NOS thus masks differences in gene expression 
in TCR_Mut and TCR_WT. 
Figure S5: Heatmap of leading edge genes in patients with or without mutations in TCR 
pathways related genes.  
Clustering was performed according to (i) the patients’ mutational status in TCR related 
pathways (mutants, red and wt, blue) and (ii) hierarchy of expression profile of leading edge 
genes grouped into two categories (T-cell activation, proliferation or both gene signatures). Only 
leading edge genes from gene sets presented in Figure 4 are shown. 
Figure S6: Overall survival (OS) of patients with (red) or without (blue) mutations in TCR 
signaling-related genes was compared using the Kaplan-Meier method.  
Analysis was performed on all 80 patients with available clinical information. Mut: mutated; 
WT: wild type; Mo: months; p: p value; HR: Hazard Ratio; CI: Confidence Interval. 
Figure S7: Analysis of allele frequencies of selected mutations in patients harboring 
mutations in multiple genes. (A) Comparison of Variant Frequencies of mutations in 13 
samples harboring mutations in TET2/DNMT3A co-occuring with RHOA, IDH2 or TCR, 
JAK/STAT, TLR signaling pathways. Mean VF of TET2/DNMT3A was compared to those of 
IDH2, RHOA or TCR, JAK/STAT, TLR signaling pathways. When mutations occurred in both 
TET2 and DNMT3A or in the same genes, the highest VF was recorded. (B) Comparison of VFs 
of mutations in 27 samples harboring mutations in RHOA co-occuring with mutations in co-
stimulatory/TCR signaling related, JAK/STAT or TLR signaling. When co-stimulatory/TCR 
related, JAK/STAT or TLR signaling mutations were co-occuring, the highest VF was taken into 
consideration. Spearman correlation coefficients were calculated for relevant data pairs. Mean 
VF were compared using a Wilcoxon matched-pairs signed rank test. 
Sample sequencing age at diagnosis stage IPI status (follow up in months) Type of sample (months after diagnostic) treatment received before biopsy source of tumor DNA source of germline DNA TCR clonality in germline DNA
TENOM04.119 WGS 69 IV 5 dead (6) relapse (5) CHOP blood (leukemic dissemination, FACS sorted) saliva negative
TENOM04.121 WGS 69 IV 3 alive (18) diagnosis none lymph node (cell suspension, FACS sorted) blood ND
TENOM04.026 WGS 70 IV 4 alive (126) diagnosis none lymph node (tissue) blood negative
TENOM04.060 WGS 71 IV 4 alive (70) diagnosis none lymph node (tissue) blood ND
TENOM28.001 WGS 66 IV 4 dead (47) diagnosis none lymph node (tissue) blood negative
TENOM07.025 WGS 48 IV 4 dead (13) diagnosis none lymph node (tissue) blood ND
TENOM07.025 WGS 48 IV 4 dead (13) refractory (2.5) CHOP lymph node (tissue) blood ND
TENOM04.120 WGS 58 III 1 alive (11) relapse (9.5) CHOP lymph node (cell suspension, FACS sorted) blood negative
TENOM04.065 WES 52 IV 2 dead (105) relapse (43) COPADEM/CYVE/CHOP lymph node (tissue) blood negative
TENOM04.081 WES 62 IV 3 dead (20.6) diagnosis none lymph node (tissue) blood negative
TENOM04.115 WES 68 IV 5 dead (10.8) relapse (4) CHOP/DHAP peritoneal effusion blood negative
Table S1. Description of the 10 AITL patients of the discovery cohort.
WGS: Whole Genome Sequencing
WES: Whole Exome Sequencing
CHOP: Cyclophosphamide Hydroxydonorubicin Oncovin Prednisone
COPADEM: Cyclophosphamide Oncovin Prednisone Adriamycine Methotrexate
CYVE: Cytarabine Etoposide
DHAP: Dexamethasone Cytarabine Cisplatin
whole cohort AITL TFH-like PTCL
p value test
N 85 72 13
sex
male 50 42 8 1 F
female 35 30 5
median age (quartile) 65 (56-74) 65 (56-75) 62 (59-67) 0.4 MW
stage
I 0 0 0 0.2 F
II 1 0 1
III 21 17 4
IV 56 49 7
LDH
>N 52 44 8 0.73 F
≤N 21 17 4
hemoglobin
<10 g/dL 21 19 2 0.48 F
≥10 g/dL 46 38 8
platelets
<100000 4 3 1 0.5 F
≥100000 60 51 9
hypergammaglobulinemia
yes 23 20 3 0.7 F
no 22 18 4
Direct coombs test
positive 28 27 1 1 F
negative 17 16 1
ECOG
0-1 39 30 9 0.12 F
2-4 34 31 3
B symptoms
yes 51 43 8 1 F
no 24 20 4
IPI group
0-2 17 12 5 0.12 F
3-5 60 53 7
First line chemotherapy
anthracyclin based 59 49 10 1 Khi2
others 17 15 2
Frontline auto SCT
yes 9 7 2 0.59 F
no 58 51 7
5 years OS 35% 37% 25% 0.88 log rank
Response to treatment*
CR 34 27 7 0.49 F
PR 11 9 2
SD 0 0 0
PD 8 8 0
Early progression*
yes 13 12 1 0.43 F
no 46 37 9
5 years OS* 39% 43% 20% 0.5 log rank
5 years PFS * 27% 30% 10% 0.35 log rank
* anthracyclin based chemotherapy
F: Fisher, MW: Mann Whitney
statistics
Table S2. Summary of the clinical features of the 85 patients of the extended cohort (72 AITL and 13 TFH-like 
PTCL cases).
Hypergammaglobulinemia is defined as gammaglobukin level>16 g/L.
SCT:stem cell transplantation.
CR complete response, PR partial response, SD stable disease, PD progressive disease.
deleted region # Chromosome Patient ID
TENOM04.119
TENOM04.026
TENOM04.119
TENOM04.026
TENOM04.119
TENOM04.121
TENOM04.119
TENOM04.121
TENOM04.119
TENOM04.026
TENOM04.119
TENOM04.121
TENOM04.119
TENOM04.121
TENOM04.119
TENOM04.026
TENOM04.121
DELETIONS
localization (bp)
MCR1 1 1 600 000 1 775 000
MCR2 2 203 100 000 204 000 000
MCR3 3 48 950 000 49 176 000
MCR4 7 4 700 000 5 970 000
MCR5 7 100 330 000 102 098 000
MCR6 8 PVT1 locus
MCR7 9 CDKN2A
MCR8 12 12 300 000 12 985 000
Table S3. Summary of minimal common regions (MCR) deleted in at least two 
of ten AITL patients with whole-genome/whole-exome sequencing (discovery 
cohort) 
GENE Pathway GENE ID Chr Patient ID mutation Position Reference allele Alternate allele  VF (%)
CDK11B Cell Cycle ENSG00000248333 1 TENOM04.026 Deletion; Homo
CDK11B Cell Cycle ENSG00000248333 1 TENOM04.119 Deletion; Homo
CDKN1B Cell Cycle ENSG00000111276 1 TENOM04.026 Deletion; Homo
CDKN1B Cell Cycle ENSG00000111276 1 TENOM04.119 Deletion; Homo
CDKN1B Cell Cycle ENSG00000111276 1 TENOM04.121 Deletion; Homo
MTOR TCR signalling ENSG00000198793 1 TENOM04.119 R2430T 11174386 C G 20.8
CEP170 Cell Cycle ENSG00000143702 1 TENOM04.115 T378I 243329049 G A 24
CEP170 Cell Cycle ENSG00000143702 1 TENOM 04.026 Gain; Het
CEP170 Cell Cycle ENSG00000143702 1 TENOM 04.119 Gain; Het
DHX9 mRNA processing ENSG00000135829 1 TENOM04.065 E629Q 182845254 G C 28.7
DHX9 mRNA processing ENSG00000135829 1 TENOM 04.026 Gain; Het
DHX9 mRNA processing ENSG00000135829 1 TENOM 04.119 Gain; Het
DOCK7 TCR signalling ENSG00000116641 1 TENOM 04.026 Deletion; Het
DOCK7 TCR signalling ENSG00000116641 1 TENOM 04.119 R1550K 62970323 C T 53
DYRK3 Epignetic ENSG00000143479 1 TENOM04.065 V465L 206821936 G T 25.4
DYRK3 Epignetic ENSG00000143479 1 TENOM 04.026 Gain; Het
DYRK3 Epignetic ENSG00000143479 1 TENOM 04.119 Gain; Het
HMCN1 ENSG00000143341 1 TENOM 04.026 Gain; Het
HMCN1 ENSG00000143341 1 TENOM 04.119 K1027T 185958651 A C 28
HMCN1 ENSG00000143341 1 TENOM 04.119 Gain; Het
JAK1 JAK_STAT signalling ENSG00000162434 1 TENOM04.026 G1097D 65301158 C T 30
KCNK2 ENSG00000082482 1 TENOM 04.026 Gain; Het
KCNK2 ENSG00000082482 1 TENOM 04.119 Y272D 215345517 T G 19
KCNK2 ENSG00000082482 1 TENOM 04.119 Gain; Het
MIA3 ENSG00000154305 1 TENOM04.065 S725X 222838777 C A 22.3
MIA3 ENSG00000154305 1 TENOM 04.026 Gain; Het
MIA3 ENSG00000154305 1 TENOM 04.119 Gain; Het
NEK2 Cell Cycle ENSG00000117650 1 TENOM04.115 L376F 211840431 C A 35.4
NEK2 Cell Cycle ENSG00000117650 1 TENOM 04.026 Gain; Het
NEK2 Cell Cycle ENSG00000117650 1 TENOM 04.119 Gain; Het
TOR1AIP2 ENSG00000169905 1 TENOM04.065 Q10P 179821772 T G 47.6
TOR1AIP2 ENSG00000169905 1 TENOM 04.026 Gain; Het
TOR1AIP2 ENSG00000169905 1 TENOM 04.119 Gain; Het
TRAF5 TCR signalling ENSG00000082512 1 TENOM04.115 N18I 211526634 A T 50
TRAF5 TCR signalling ENSG00000082512 1 TENOM 04.026 Gain; Het
TRAF5 TCR signalling ENSG00000082512 1 TENOM 04.119 Gain; Het
DOCK10 TCR signalling ENSG00000135905 2 TENOM04.115 V1038L 225688289 C A 43.4
DOCK10 TCR signalling ENSG00000135905 2 TENOM04.026 P903S 225704744 G A 37
FSIP2 ENSG00000188738 2 TENOM04.026 R309C 186611436 C T 28
FSIP2 ENSG00000188738 2 TENOM04.119 I688L 186653658 A C 24
FSIP2 ENSG00000188738 2 TENOM04.119 I5382L 186669910 A C 47
FSIP2 ENSG00000188738 2 TENOM04.119 K6078T 186671999 A C 19
RHOA TCR signalling ENSG00000067560 3 TENOM04.026 G17V 49412973 C A 26
RHOA TCR signalling ENSG00000067560 3 TENOM28.001 G17V 49412973 C A 18
RBP7 ENSG00000162444 3 TENOM 04.119 Deletion; Het
RBP7 ENSG00000162444 3 TENOM04.026 Deletion; Het
CTNNB1 TCR signalling ENSG00000168036 3 TENOM04.026 G34E 41266104 G A 15
TET2 Epignetic ENSG00000168769 4 TENOM04.120 Q1034X 106193748 C T 21
TET2 Epignetic ENSG00000168769 4 TENOM04.120 R206X 106413197 C T 21
TET2 Epignetic ENSG00000168769 4 TENOM07.025 G898X 106157791 G T 9
TLR6 TLR signalling ENSG00000174130 4 TENOM04.065 D610Y 38829267 C A 32.9
TLR6 TLR signalling ENSG00000174130 4 TENOM 04.119 Gain; Het
WDFY3 Autophagy ENSG00000163625 4 TENOM04.065 L1721F 85686988 T A 33.7
WDFY3 Autophagy ENSG00000163625 4 TENOM 04.119 M1299T 85708640 A G 30
WDFY3 Autophagy ENSG00000163625 4 TENOM 04.119 K488T 85742365 T G 38
DNAH8 ENSG00000124721 6 TENOM04.06 I3597T 38899753 T C 26.5
DNAH8 ENSG00000124721 6 TENOM04.119 R3949X 38939412 C T 45
FYN TCR signalling ENSG00000010810 6 TENOM 04.119 Deletion; homo
FYN TCR signalling ENSG00000010810 6 TENOM04.026 Deletion; Het
MDN1 ENSG00000112159 6 TENOM04.065 D364Y 90499886 C A 19.5
MDN1 ENSG00000112159 6 TENOM 04.119 D4565N 90382020 C T 54
MDN1 ENSG00000112159 6 TENOM04.026 Deletion; Het
GTF2I TCR signalling ENSG00000077809 7 TENOM04.081 L607F 74159167 G C 22.9
GTF2I TCR signalling ENSG00000077809 7 TENOM 04.119 Deletion; Het
GTF2I TCR signalling ENSG00000077809 7 TENOM04.121 Deletion; Het
SPDYE2 ENSG00000205238 7 TENOM04.081 F94L 102198956 T C 21.5
SPDYE2 ENSG00000205238 7 TENOM 04.026 Gain; Het
SPDYE2 ENSG00000205238 7 TENOM 04.121 Gain; Het
PVT1 ENSG00000249859 8 TENOM04.119 Deletion; Homo
PVT1 ENSG00000249859 8 TENOM04.121 Deletion; Homo
CDKN2A Cell Cycle ENSG00000147889 9 TENOM04.119 Deletion; Homo
CDKN2A Cell Cycle ENSG00000147889 9 TENOM04.121 Deletion; Homo
DDX58 mRNA processing ENSG00000107201 9 TENOM04.081 D502Y 32467832 C A 40.9
DDX58 mRNA processing ENSG00000107201 9 TENOM04.026 M204T 32491379 A G 14
DMBT1 ENSG00000187908 10 TENOM04.065 S643P 124361393 T C 39.2
DMBT1 ENSG00000187908 10 TENOM04.119 S1052T 124358487 T A 50
DMBT1 ENSG00000187908 10 TENOM04.121 Deletion; Het
CREBL2 TCR signalling ENSG00000111269 12 TENOM04.026 Deletion; Homo
CREBL2 TCR signalling ENSG00000111269 12 TENOM04.119 Deletion; Homo
CREBL2 TCR signalling ENSG00000111269 12 TENOM04.121 Deletion; Homo
DUSP16 TCR signalling ENSG00000111266 12 TENOM04.026 Deletion; Homo
DUSP16 TCR signalling ENSG00000111266 12 TENOM04.119 Deletion; Homo
DUSP16 TCR signalling ENSG00000111266 12 TENOM04.121 Deletion; Homo
LRP6 Wint signalling ENSG00000070018 12 TENOM04.026 Deletion; Homo
LRP6 Wint signalling ENSG00000070018 12 TENOM04.119 Deletion; Homo
LRP6 Wint signalling ENSG00000070018 12 TENOM04.119 E180V 12356245 T A 42
LRP6 Wint signalling ENSG00000070018 12 TENOM04.121 Deletion; Homo
PIK3C2G TCR signalling ENSG00000139144 12 TENOM04.065 V453A 18491445 T C 23.3
GOLGA8B ENSG00000215252 15 TENOM04.081 T132I 34823738 G A 25.4
GOLGA8B ENSG00000215252 15 TENOM 028.001 Gain; Het
GOLGA8B ENSG00000215252 15 TENOM 04.060 Gain; Het
CREBBP TCR signalling ENSG00000005339 16 TENOM04.119 Deletion; Homo
KRT20 ENSG00000171431 17 TENOM 04.060 Gain; Het
KRT20 ENSG00000171431 17 TENOM 04.119 E406D 39032670 T G 46
NLRP4 Autophagy ENSG00000160505 19 TENOM04.065 T162M 56369244 C T 28.4
NLRP4 Autophagy ENSG00000160505 19 TENOM04.119 R810H 56382267 G A 25
TPRX1 ENSG00000178928 19 TENOM 04.119 Deletion; Het
TPRX1 ENSG00000178928 19 TENOM04.121 Deletion; Het
VAV1 TCR signalling ENSG00000141968 19 TENOM04.119 R822Q 6805090 G A 91
IFNAR2 IFNgamma signalling ENSG00000159110 21 TENOM 04.026 Gain; Het
IFNAR2 IFNgamma signalling ENSG00000159110 21 TENOM 04.121 W54X 34617320 G A 18
IFNAR2 IFNgamma signalling ENSG00000159110 21 TENOM 08.001 Gain; Het
F8 ENSG00000185010 X TENOM04.065 A68V 154090108 G A 28.8
F8 ENSG00000185010 X TENOM 04.119 K1459T 153810883 T G
F8 ENSG00000185010 X TENOM 04.119 Gain; Het
MAGEC1 ENSG00000155495 X TENOM 04.119 S535G 140994793 A G 81
MAGEC1 ENSG00000155495 X TENOM 04.119 Gain; Het
MAGEC1 ENSG00000155495 X TENOM 04.121 Gain; Het
BEND2 ENSG00000177324 X TENOM04.026 M572L 18194130 T A 22
BEND2 ENSG00000177324 X TENOM04.065 N542Y 18192234 T A 24.9
Table S4. Significant gene alterations found in the discovery cohort. Summary of SNVs and CNVs of 39 genes altered in at least two patients of 10 AITL patients 
subject to WG/ES and variants in 6 genes related to TCR signaling pathway found mutated in one patient each. Genes are arranged by chromosome number and position. 
Variants are presented according to GRCh37 assembly (Ensembl). VF: Variant frequency; Chr: chromosome; Homo:homozygous; Het: heterozygous
HGVS name ensembl # localization (chr:start-end:strand) targeted function pathway
AKT1 ENSG00000142208 14:105235686-105262088:-1 exons kinase TCR signalling
AKT2 ENSG00000105221 19:40736224-40791443:-1 exons kinase TCR signalling
BCL6 ENSG00000113916 3:187439165-187463515:-1 exons transcription factor TCR signalling
BRAF ENSG00000157764 7:140,419,127-140,624,564:-1 exons kinase TCR signalling
CARD11 ENSG00000198286 7:2,945,775-3,083,579:-1 exons TCR signalling
CD28 ENSG00000178562 2:204571198-204602557:+1 exons receptor TCR signalling
CDC42 ENSG00000070831 1:22379120-22419437:+1 exons small GTPase TCR signalling
CDK11B ENSG00000248333 1:1570603-1590473:-1 exons cyclin Cell Cycle
CDKN1B ENSG00000111276 12:12867992-12875305:+1 exons cyclin inhibitor Cell Cycle
CDKN2A ENSG00000147889 9:21967751-21995300:-1 exons cyclin inhibitor Cell Cycle
CEP170 ENSG00000143702 1:243287730-243418650:-1 exons centrosome component Cell Cycle
CREBBP ENSG00000005339 16:3775055-3930727:-1 exons transcription factor TCR signalling
CREBL2 ENSG00000111269 12:12764761-12798042:+1 exons transcription factor TCR signalling
CTNNB1 ENSG00000168036 3:41236328-41301587:+1 exons transcription factor TCR signalling
CTNND1 ENSG00000198561 11:57520715-57587018:+1 exons GAP TCR signalling
DDX58 ENSG00000107201 9:32455300-32526322:-1 exons RNA helicase mRNA processing
DHX9 ENSG00000135829 1:182808504-182856886:+1 exons RNA helicase mRNA processing
DMBT1 ENSG00000187908 10:124320181-124403252:+1 exons transcription factor unknown
DOCK10 ENSG00000135905 2:225629807-225907162:-1 exons GEF TCR signalling
DOCK5 ENSG00000147459 8:25042238-25275598:+1 exons GEF TCR signalling
DOCK7 ENSG00000116641 1:62920399-63153969:-1 exons GEF TCR signalling
DUSP16 ENSG00000111266 12:12628829-12715317:-1 exons MAPK phosphatase TCR signalling
DYRK2 ENSG00000127334 12:68042118-68059186:+1 exons kinase Epigenetic
DYRK3 ENSG00000143479 1:206808881-206857764:+1 exons kinase Epigenetic
FYN ENSG00000010810 6:111981535-112194655:-1 exons kinase TCR signalling
GSK3β ENSG00000082701 3:119540170-119813264:-1 exons kinase TCR signalling
GTF2I ENSG00000077809 7:74071994-74175026:+1 exons transcription factor TCR signalling
ICOS ENSG00000163600 2:204801471-204826300:+1 exons receptor TCR signalling
IFNAR2 ENSG00000159110 21:34602206-34637969:+1 exons receptor Receptor
IRF4 ENSG00000137265 6:391739-411447:+1 exons transcription factor TCR signalling
ITK ENSG00000113263 5:156569944-156682201:+1 exons kinase TCR signalling
JAK1 ENSG00000162434 1:65,298,912-65,432,187:-1 hotspots kinase JAKs_STATs signalling
JAK2 ENSG00000096968 9:4,985,033-5,128,183:+1 hotspots kinase JAKs_STATs signalling
JAK3 ENSG00000105639 9:17,935,589-17,958,880:-1 hotspots kinase JAKs_STATs signalling
KRAS ENSG00000133703 12:25,357,723-25,403,870:-1 exons kinase TCR signalling
LAT ENSG00000213658 16:28,984,826-28,990,783:+1 exons molecular bridge TCR signalling
LCK ENSG00000182866 1:32716840-32751766:+1 exons kinase TCR signalling
LRP6 ENSG00000070018 12:12268959-12419946:-1 exons co-receptor Wint signalling
MAF ENSG00000178573 16:79619740-79634611:-1 exons transcription factor TCR signalling
MAPK1 ENSG00000100030 22:22108789-22221970:-1 exons kinase TCR signalling
MAPK3 ENSG00000102882 16:30125426-30134827:-1 exons kinase TCR signalling
MAPK8 ENSG00000107643 10:49514698-49647403:+1 exons kinase TCR signalling
MAPK9 ENSG00000050748 5:179660143-179719099:-1 exons kinase TCR signalling
MDN1 ENSG00000112159 6:90352218-90529442:-1 exons nuclear chaperonne nuclear chaperonne
MYD88 ENSG00000172936 3:38,179,969-38,184,513:+1 hotspots adaptor protein TLR signalling
NEK2 ENSG00000117650 1:211836114-211848960:-1 exons kinase Cell Cycle
NEK6 ENSG00000119408 9:127019885-127115586:+1 exons kinase Cell Cycle
NLRP4 ENSG00000160505 19:56347944-56393220:+1 exons pattern recognition receptor Autophagy
PDPK1 ENSG00000140992 16:2587965-2653189:+1 exons kinase TCR signalling
PIK3CA ENSG00000121879 3:178865902-178957881:+1 exons PIK3 catalytic subunit TCR signalling
PIK3CB ENSG00000051382 3:138372860-138553780:-1 exons PIK3 catalytic subunit TCR signalling
PIK3CG ENSG00000105851 7:106505723-106547590:+1 exons PIK3 catalytic subunit TCR signalling
PIK3R1 ENSG00000145675 5:67511548-67597649:+1 exons PIK3 regulatory subunit TCR signalling
PIK3R5 ENSG00000141506 17:8782233-8869029:-1 exons PIK3 regulatory subunit TCR signalling
PLCG1 ENSG00000124181 20:39765600-39825427:+1 exons kinase TCR signalling
PLCG2 ENSG00000197943 16:81772702-81991899:+1 exons kinase TCR signalling
PRKCQ ENSG00000065675 10:6,469,105-6,622,263:-1 exons kinase TCR signalling
RAC1 ENSG00000136238 7:6414154-6443608:+1 exons small GTPase TCR signalling
RHOA ENSG00000067560 3:49396578-49450431:-1 exons small GTPase TCR signalling
STAT3 ENSG00000168610 17:40,465,342-40,540,586:-1 hotspots transcription factor TCR and JAKs_STATs signalling
STAT4 ENSG00000138378 2:191,894,302-192,016,322:-1 hotspots transcription factor JAKs_STATs signalling
STAT5B ENSG00000173757 17:40,351,186-40,428,725:-1 hotspots transcription factor JAKs_STATs signalling
TPRX1 ENSG00000178928 19:48304500-48322308:-1 exons transcription factor Transcription factor
TRAF5 ENSG00000082512 1:211499957-211548288:+1 exons scaffold protein TCR signalling
TRAF6 ENSG00000175104 11:36,508,577-36,531,822:-1 exons E3 ubiquitin ligase TCR signalling
VAV1 ENSG00000141968 19:6772725-6857377:+1 exons GEF TCR signalling
VAV2 ENSG00000160293 9:136627016-136857726:-1 exons GEF TCR signalling
WDFY3 ENSG00000163625 4:85590704-85887544:-1 exons scaffold protein - PIP3 binding prot Autophagy
ZAP70 ENSG00000115085 2:98,330,023-98,356,325:+1 exons kinase TCR signalling
Table S5. List of 69 genes analyzed by targeted deep sequencing. The 27 genes in boldface were selected from WG/ES of the discovery cohort. Genes found alteres in 
whole genome / whole exome sequencing are in bold face.
GENE uniprot # #CHROM POSITION ID Nucleotide Change Amino Acid Change Mutation type domain somatic in cosmic VF (mean) VF (min) VF (max) # (AITL) # (TFH-like) Filtered out SIFT PROVEAN Polyphen-2
CDK11B P21127 1 1577072 . NM_033489:exon10:c.846_851del 282_284del non frameshift deletion Glu rich domain 0.19 0.19 0.19 1 0 NA NA NA
JAK1 P23458 1 65307195 . NM_002227:exon18:c.2493C>A D831E missense kinase domain 0.05 0.05 0 1 Deleterious Damaging  probably damaging
LCK
 P06239 1 32751125 . b;NM_001042771:exon13:c.1338C>A b;N446K missense kinase domain 0.26 0.26 0.26 1 0 Neutral Tolerated  probably damaging
LCK 1 32751127 . b;NM_001042771:exon13:c.1340C>G:p.P447R b;P447R missense kinase domain 0.26 0.26 0.26 1 0 Deleterious Damaging  probably damaging
DOCK7 Q96N67 1 63042973 . NM_033407:exon18:c.2072T>C L691S missense DHR-1 domaim 0.48 0.48 0.48 0 1 yes Neutral Tolerated  probably damaging
DYRK3 O43781 1 206811055 . NM_003582:exon2:c.138T>G C46W missense 0.53 0.53 0.53 1 0 yes Neutral Tolerated  probably damaging
TRAF5 O00463 1 211526601 . :NM_145759:exon2:c.20A>G H7R missense 0.53 0.53 0.53 0 1 yes Deleterious Damaging             benign
CEP170 Q5SW79 1 243362476 . NM_001042404:exon7:c.517G>T G173C missense 0.04 0.04 0.04 1 0 Neutral Tolerated  possibly damaging
CD28  P10747 2 204591674 . NM_006139:exon2:c.371A>T D124V missense extracellular 0.12 0.09 0.16 2 0 Neutral Tolerated  possibly damaging
CD28 2 204591675 . NM_006139:exon2:c.372C>A D124E missense extracellular 0.11 0.07 0.12 2 0 Neutral Tolerated  possibly damaging
CD28 2 204599555 . NM_006139:exon4:c.583A>C T195P missense cytoplasmic 0.24 0.11 0.38 4 0 Deleterious Damaging             benign
MYD88 P22366 3 38182032 . NM_001172567:exon3:c.656C>G S219C missense TIR domain yes 0.40 0.40 0.40 0 1 Deleterious Damaging  possibly damaging
CTNNB1 P35222 3 41266124 . a;
 NM_001904:exon3:c.122A>G a; T41A missense Phospho by GSK3b yes 0.09 0.05 0.12 1 1 Deleterious Damaging  possibly damaging
CTNNB1 3 41266110 . NM_001904:exon3:c.107A>C H36P missense yes 0.15 0.15 0.15 1 0 Deleterious Damaging  possibly damaging
CTNNB1 3 41266137 . a;
 NM_001904:exon3:c.134C>T a; S45F missense yes 0.03 0.03 0.03 2 0 Deleterious Damaging  possibly damaging
CTNNB1 3 41268766 . NM_001904:exon7:c.1004A>C K335T missense yes 0.13 0.08 0.17 2 0 Deleterious Damaging  possibly damaging
RHOA P61586 3 49412969 . NM_001664:exon2:c.54G>T K18N missense GTP binding 0.08 0.06 0.10 3 0 Deleterious Damaging  possibly damaging
RHOA 3 49412973 rs11552761 NM_001664:exon2:c.50G>T G17V missense GTP binding yes 0.15 0.02 0.39 42 6 Neutral Tolerated  possibly damaging
PIK3CB P42338 3 138433476 . NM_006219:exon7:c.1136A>G H379R missense C2 PI3K-type 0.50 0.50 0.50 1 0 yes Deleterious Damaging  possibly damaging
PIK3CA P42336 3 178951947 . NM_006218:exon21:c.3002T>C L1001P missense PI3K/PI4K 0.02 0.02 0.02 0 1 Deleterious Damaging  possibly damaging
WDFY3 Q8IZQ1 4 85758240 . NM_014991:exon7:c.418A>C: T140P missense 0.09 0.09 0.09 1 0 Neutral Tolerated  possibly damaging
PIK3R1 P27986 5 67569305 . NM_181523exon3:c.422A>G K141R missense RHO-GAP 0.02 0.02 0.02 0 1 Deleterious Damaging             benign
PIK3R1 5 67589661 . NM_181523:exon11:c.1424A>C Q475P missense iSH2 0.02 0.02 0.02 1 0 Neutral Tolerated  possibly damaging
PIK3R1 5 67591133 . NM_181523:exon13:c.1726A>G T576A missense iSH2 0.02 0.02 0.02 0 1 Deleterious Damaging             benign
PIK3R1 5 67593292 . NM_181523:exon16:c.2038G>A G680S missense SH2 2 0.04 0.04 0.04 0 1 Neutral Damaging  possibly damaging
PIK3R1 5 67593364 . NM_181523:exon16:c.2110G>A V704M missense SH2 2 0.04 0.04 0.04 1 0 Deleterious Damaging  possibly damaging
IRF4 Q15306 6 394867 rs202124383 NM_002460:exon3:c.263C>A P88Q missense DNA binding 0.48 0.48 0.48 1 0 yes Deleterious NA  possibly damaging
MDN1 Q9NU22 6 90372565 . NM_014611:exon86:c.14355_14357del 4785_4786del non frameshift deletion poly glu 0.43 0.43 0.43 1 0 yes NA NA NA
MDN1 6 90415827 . NM_014611:exon53:c.8099T>C L2700P missense 0.51 0.51 0.51 1 0 yes Deleterious Tolerated  possibly damaging
MDN1 6 90428552 . M_014611:exon42:c.6255C>G H2085Q missense near ATP binding 0.39 0.39 0.39 1 0 Neutral Tolerated             benign
MDN1 6 90481323 . NM_014611:exon15:c.2101G>A V701I missense near ATP binding 0.11 0.11 0.11 0 1 Deleterious Damaging             benign
MDN1 6 90482411 . NM_014611:exon14:c.1964C>T P655L missense near ATP binding 0.50 0.50 0.50 1 0 yes NA NA             benign
FYN P06241 6 111982968 . NM_153047:exon11:c.1579C>T Q527X stop gain 0.05 0.05 0.06 1 0 NA NA  possibly damaging
FYN 6 111982971 . a;NM_153047:exon11:c.1574_1575del a;525_525del frameshift deletion 0.07 0.07 0.07 0 1 Deleterious Damaging NA
FYN 6 112024228 . a;NM_153047:exon5:c.557C>T a;S186L missense SH2 domain 0.16 0.16 0.16 0 1 NA NA  possibly damaging
FYN 6 112035569 . b;
 NM_153047:exon2:c.324delA b; K108fs frameshift deletion 0.10 0.10 0.10 1 0 Deleterious Damaging  possibly damaging
FYN 6 112035573 . b;
 NM_153047:exon2:c.321AAG>TCT b; E107S missense SH3 domain 0.10 0.10 0.10 1 0 Deleterious Damaging  possibly damaging
CARD11 Q9BXL7 7 2955005 . NM_032415:exon21:c.2705T>G F902C missense 0.06 0.06 0.06 1 0 Neutral Damaging  possibly damaging
CARD11 7 2969640 . NM_032415:exon12:c.1639T>A S547T missense 0.05 0.05 0.05 0 1 Deleterious Damaging             benign
CARD11 7 2984003 . NM_032415:exon5:c.527T>G F176C missense coiled coil 0.49 0.49 0.49 1 0 Neutral Tolerated  possibly damaging
GTF2I  P78347 7 74143131 . NM__032999:exon13:c.951T>G D317E missense 0.17 0.17 0.17 1 0 Neutral Tolerated             benign
GTF2I 7 74143199 . NM_032999:exon13:c.1019A>G N340S missense 0.21 0.21 0.21 0 1 Neutral Tolerated             benign
GTF2I 7 74150975 . NM__032999:exon18:c.1569G>T R523S missense GTF2I-like 0.17 0.17 0.17 1 0 Neutral Damaging  possibly damaging
GTF2I 7 74159167 . NM_032999:exon21:c.1821G>C L607F missense GTF2I-like yes 0.25 0.25 0.25 1 0 Neutral Tolerated  possibly damaging
GTF2I 7 74162388 . NM_032999:exon24:c.2105G>A R702Q missense 0.18 0.18 0.18 1 0 Neutral Tolerated             benign
PIK3CG P48736 7 106508166 . NM_002649:exon2:c.160C>G P54A missense PI3K-ABD 0.49 0.49 0.49 1 0 yes Neutral Tolerated             benign
DOCK5 Q9H7D0 8 25240226 . NM_024940:exon40:c.4063G>T A1355S missense DHR-2 domain 0.49 0.49 0.49 0 1 yes Neutral Damaging             benign
CDKN2A P42771 9 21968733 . NM_001195132:exon3:c.495G>C R165S missense 0.44 0.44 0.44 1 0 yes Neutral Tolerated  possibly damaging
DDX58 O95786 9 32488079 . NM_014314:exon8:c.1076C>T T359M missense Helicase ATP-binding no 0.48 0.48 0.48 1 0 yes Deleterious Damaging  possibly damaging
JAK2 O60674 9 5073770 rs77375493 NM_004972:exon14:c.1849G>T V617F missense yes 0.15 0.15 0.15 1 0 Neutral Damaging  possibly damaging
VAV2 P52735 9 136674187 . NM_001134398:exon7:c.641A>G Y214C missense DH domain yes 0.57 0.57 0.57 1 0 NA NA  possibly damaging
DMBT1 Q9UGM3 10 124325492 . NM_017579:exon2:c.72_79del 24_27del frameshift deletion 0.44 0.44 0.44 1 0 yes NA NA NA
DMBT1 10 124342406 . NM_017579:exon13:c.1357C>G Q453E missense SRCR 3 0.61 0.61 0.61 1 0 yes Neutral Tolerated  possibly damaging
DMBT1 10 124348727 . NM_017579:exon16:c.2021A>G N674S missense SRCR 5 0.86 0.86 0.86 1 0 yes Deleterious Tolerated             benign
DMBT1 10 124366695 . NM_017579:exon29:c.3658C>T P1220S missense SRCR 9 1.00 1.00 1.00 0 1 yes NA NA             benign
TRAF6 Q9Y4K3 11 36511918 . NM_004620:exon7:c.1039C>T Q347X stop gain coiled coil /MATH 0.14 0.14 0.14 1 0 Neutral Tolerated  possibly damaging
TRAF6 11 36518706 . NM_145803:exon5:c.558G>T Q186H missense TRAF-type 1 0.50 0.50 0.50 1 0 yes Neutral Tolerated  possibly damaging
LRP6 O75581 12 12278241 . NM_002336:exon21:c.4438T>A Y1480N missense PPPSP motif A 0.17 0.17 0.17 1 0 Neutral Tolerated  possibly damaging
LRP6 12 12291358 . NM_002336:exon16:c.3508A>G I1170V missense LDL-receptor class B 20 0.45 0.45 0.45 1 0 yes Deleterious Damaging             benign
LRP6 12 12334271 rs141212743 NM_002336:exon6:c.1079G>A R360H missense Beta-propeller 2 0.51 0.51 0.51 1 0 yes Neutral Damaging  possibly damaging
KRAS  P01116 12 25398211 . NM_004985:exon2:c.108A>G I36M missense no 0.03 0.03 0.03 0 1 Deleterious Damaging  possibly damaging
KRAS 12 25398266 . NM_004985:exon2:c.53C>A A18D missense GTP binding no 0.03 0.03 0.03 1 0 Deleterious Damaging  possibly damaging
KRAS 12 25398281 . NM_033360:exon2:c.38G>A G13D missense GTP binding yes 0.25 0.25 0.25 0 1 Deleterious Damaging  possibly damaging
AKT1 P31749 14 105239665 . NM_001014431:exon10:c.880G>A G294R missense protein kinase 0.33 0.33 0.33 1 0 Neutral NA  possibly damaging
PDPK1  O15530 16 2607734 . NM_002613:exon2:c.56_58del 19_20del non frameshift deletion 0.32 0.32 0.32 1 0 NA NA NA
PDPK1 16 2611895 . NM_002613:exon4:c.453_456del 151_152del frameshift deletion protein kinase 0.28 0.28 0.28 1 0 Deleterious Damaging NA
PDPK1 16 2633432 . NM_002613:exon10:c.971G>A R324Q missense protein kinase 0.31 0.31 0.31 1 0 Deleterious Tolerated  possibly damaging
PDPK1 16 2633480 . NM_002613:exon10:c.1019C>A P340Q missense protein kinase 0.27 0.27 0.27 1 0 Neutral Tolerated             benign
PDPK1 16 2636756 rs75824263 NM_002613:exon11:c.1205C>T T402M missense 0.49 0.19 0.49 1 0 yes Deleterious Tolerated  possibly damaging
LAT O43561 16 28997042 rs55945024 NM_001014989:exon3:c.217G>A D73N missense 0.52 0.52 0.52 0 1 yes Deleterious Tolerated  possibly damaging
LAT 16 28997459 . NM_001014989:exon5:c.275C>T T92M missense 0.47 0.47 0.47 1 0 yes Deleterious Damaging  possibly damaging
CREBBP Q92793 16 3781835 . NM_004380:exon29:c.4832C>T P1611L missense Interaction with TRERF1 0.44 0.44 0.44 1 0 yes Neutral Damaging  possibly damaging
CREBBP 16 3900638 rs146538907 NM_004380:exon2:c.458C>T P153L missense 0.61 0.51 0.71 2 0 yes Deleterious Damaging  possibly damaging
MAPK3 P27361 16 30128549 . NM_001040056:exon6:c.833G>A R278Q missense protein kinase 0.02 0.02 0.02 1 0 Deleterious Damaging  possibly damaging
MAPK3 16 30129406 . NM_002746:exon4:c.622C>T R208C missense protein kinase 0.50 0.50 0.50 1 0 yes Neutral Tolerated  possibly damaging
PLCG2  P16885 16 81819700 . NM_002661:exon2:c.106T>C S36P missense PH domain 0.58 0.58 0.58 1 0 yes Neutral Damaging             benign
PLCG2 16 81957181 . NM_002661:exon22:c.2399C>G S800C missense SH3 domain 0.48 0.48 0.48 1 0 yes Deleterious Damaging  possibly damaging
STAT3 P40763 17 40475063 . NM_139276:exon20:c.1847A>G E616G missense SH2 domain yes 0.03 0.03 0.03 1 0 Deleterious Damaging  possibly damaging
STAT3 17 40475064 . NM_139276:exon20:c.1846G>A E616K missense SH2 domain yes 0.04 0.04 0.04 1 0 Neutral Tolerated             benign
PIK3R5 Q8WYR1 17 8793325 . NM_014308:exon8:c.776C>T A259V missense yes 0.53 0.53 0.53 1 0 NA NA  possibly damaging
VAV1 P15498 19 6822232 . NM_005428:exon5:c.451_472del 151_158del frameshift deletion 0.14 0.14 0.14 1 0 Deleterious Damaging NA
VAV1 19 6826639 . NM_005428:exon9:c.844C>T R282C missense DH domain 0.44 0.44 0.44 1 0 yes NA NA  possibly damaging
VAV1 19 6853948 . NM_005428:exon26:c.2333_2348del 778_783del frameshift deletion 0.06 0.06 0.06 1 0 Deleterious Damaging             benign
VAV1 19 6854015 . NM_005428:exon26:c.2390A>G D797G missense SH3 2 domain 0.15 0.15 0.15 1 0 Neutral Tolerated  possibly damaging
VAV1 19 6854102 . NM_005428:exon26:c.2477A>C Y826S missense SH3 2 domain 0.07 0.07 0.07 0 1 Neutral Tolerated  possibly damaging
JAK3 P52333 19 17945764 rs201784993  NM_000215:exon16:c.2096C>T A699V missense kinase domain yes 0.45 0.45 0.45 1 0 Neutral Damaging  possibly damaging
TPRX1  Q8N7U7 19 48306003 . NM_198479:exon2:c.265C>T P89S missense 0.44 0.44 0.44 0 1 yes Deleterious Damaging  possibly damaging
NLRP4 Q96MN2 19 56369244 rs117212164 NM_134444:exon3:c.485C>T T162M missense NACHT domain yes 0.48 0.46 0.50 1 1 Deleterious Damaging  possibly damaging
NLRP4 19 56363459 . NM_134444:exon2:c.13T>G F5V missense DAPIN domain 0.05 0.05 0.05 0 1 Deleterious Damaging  possibly damaging
PLCG1 P19174 20 39766420 . NM_182811:exon1:c.139G>A E47K missense PH 1 domain 0.06 0.06 0.06 0 1 Deleterious Damaging  possibly damaging
PLCG1 20 39766423 . NM_182811:exon1:c.142C>T R48W missense PH 1 domain 0.18 0.18 0.18 1 0 Deleterious Damaging  possibly damaging
PLCG1 20 39792575 . NM_182811:exon11:c.1025A>G D342G missense PI-PLC X-box domain 0.05 0.05 0.05 0 1 Deleterious Damaging  possibly damaging
PLCG1 20 39792584 . a;
 NM_182811:exon11:c.1034C>T a; S345F missense PI-PLC X-box domain yes 0.11 0.04 0.19 1 1 Deleterious Damaging  possibly damaging
PLCG1 20 39794139 . a;
 NM_182811:exon15:c.1559C>T a; S520F missense PH 2; first part yes 0.04 0.02 0.04 2 0 Neutral Tolerated  possibly damaging
PLCG1 20 39795386 . NM_182811:exon19:c.2188G>A E730K missense SH2 2 domain 0.15 0.15 0.15 1 0 Deleterious Damaging  possibly damaging
PLCG1 20 39798122 . NM_002660:exon23:c.2606G>A G869E missense near SH3 domain 0.07 0.03 0.10 2 0 Deleterious Damaging  possibly damaging
PLCG1 20 39802073 . NM_182811:exon28:c.3293G>A R1098Q missense C2 domain 0.48 0.48 0.48 1 0 yes Deleterious Damaging  possibly damaging
PLCG1 20 39802384 . NM_182811:exon29:c.3487G>A E1163K missense C2 domain yes 0.15 0.15 0.15 0 1 Deleterious Damaging  possibly damaging
PLCG1 20 39802390 . NM_182811:exon29:c.3493G>C D1165H missense C2 domain 0.37 0.37 0.37 0 1 Deleterious Damaging  possibly damaging
PLCG1 20 39802391 . NM_182811:exon29:c.3494A>G D1165G missense C2 domain 0.04 0.04 0.04 1 0 Neutral Tolerated  possibly damaging
IFNAR2 P48551 21 34619127 . a;
 NM_207585:exon5:c.326T>C a; V109A missense extracellular 0.55 0.55 0.55 1 0 yes Neutral Damaging             benign
IFNAR2 21 34635801 rs45513593 a;
 NM_207585:exon9:c.1544G>A a; R515K missense cytoplasmique no 0.54 0.54 0.54 1 0 yes Neutral Tolerated  possibly damaging
MAPK1 P28482 22 22161975 rs202041676 NM_138957:exon2:c.280A>G T94A missense 0.55 0.55 0.55 1 0 yes NA NA             benign
Table S6. List of crossvalidated variants identified by Targeted Deep Sequencing of 69 candidate genes in 85 AITL and TFH-like PTCL samples. 103 variants were found in 45/69 candidate genes analyzed. Genes are arranged by chromosome number and position. Variants are presented according to GRCh37 assembly (Ensembl). 
VF: Variant Frequency. 
a
: denotes variants found in the same patient in different alleles. 
b
: denotes variants found in the same patient in the same allele.
Signature name number of genes Up Down Leading edge genes symbols Category Remarks
ABC_gt_GCB_PMBL_MCL_BL_U133AB 51 0.00359964 0.99160084 ABHD17C,PIM2,RAB7L1 T cell activation
ABCgtGCB_U133AB 273 0.0209979 0.96050395 CKAP4,ABHD17C,FUT8,LARP1B,PIM2,RAB7L1,SCN2A T cell activation
ABC_gt_GCB_Affy 20 0.02559744 0.98190181 FUT8,PIM2 T cell activation
IRF4_myeloma_induced_all 289 0.03019698 0.97530247 ANKRD37,GFPT1,KLK1,MTHFD1L,PDIA4,PDS5A,PIM2 T cell activation
IRF4_myeloma_induced_direct 37 0.04129587 0.839916008 GFPT1,PIM2 T cell activation
Blood_Module-1.4_Undetermined 97 0.029997 0.920807919 BTG3,CDCA4,CREM,CYLD,EIF5,EPC1,PTP4A1,ZNF331 T cell activation
Tcell_PIind_CalciumDefPtdown4x_Feske_Fig4 59 0.0289971 0.923707629 LTA,TMCC2,ZBED2 T cell activation
Thymic_DP_Tcell_gt_Thymic_SP_CD4+Tcell 102 0.01509849 0.874812519 C17orf67,CD8A,CPVL,E2F7,SH2D1A T cell activation
HALLMARK_MTORC1_SIGNALING 197 0.049295071 0.98360164 IFRD1,PLOD2,PSPH,SLC7A11,ELOVL6,CYB5B,RPN1,NUFIP1 T cell activation
JAK_Up_HBL1 328 0.03039696 0.97130287 HOOK3,KBTBD6,KRT71,MTHFD1L,SLC4A7,SYCN,TMED9 T cell activation
Tcell_cytokine_induced_IL2_IL7_IL15only 23 0.00729927 0.97140286 LTA T cell activation
Tcell_cytokine_induced_PMBC_Bcell_induced 29 0.04489551 0.9740026 CREM,DNAJC3 T cell activation
HALLMARK_KRAS_SIGNALING_DN 197 0.940605939 0.0169983 MAGIX,ARHGDIG,KCNQ2,SLC30A3,SSTR4,PNMT,TLX1 T cell activation
E2F3_overexpression_2x_up 135 0.00529947 0.99690031 CDC20B,CRELD2,E2F7,KIAA1804 Proliferation
Cell_cycle_Cho 508 0.04249575 0.99650035 BMPR1A,TIMMDC1,ELOVL6,EPC1,ETV1,FUT8,KLF5,LRRC8B,MOGAT2,NF2,PTPRR,STAM2,SYNGAP1,XIAP,ZFAND5 Proliferation
T_cell 14 0.9310138 0.101257748 SH2D1A Proximal TCR signalling elements Marginal significance
Table S7. Leading edge genes from GSEA analysis comparing GEP profiles of samples according to the mutational status for TCR signaling genes (mutated versus wild type). The p-values for upregulated (Up) and downregulated (Down) pathways in patients 
harbouring mutations are reported, together with the genes with the highest correlation to the mutation status (“Leading edge genes”); genes indicated in boldface are differentially expressed in TCR_Mut versus TCR_WT cases.
WES WES TDS TDS TDS TDS TDS TDS
diagnostic refractory (2.5) diagnostic refarctory (1) diagnostic relapse (13) diagnostic relapse (7)
#CHROM GENE POSITION REF ALT ID CHANGE effect domain somatic in cosmic Filtered out 
4 TET2 . . . . c. 1516insG:p.Cys484fs frameshift . . . 8.06 7.74
4 TET2 . . . . c.2937_2938insA:p.Gln958fs frameshift . . . ND ND NA NA
4 TET2 106180929 . TTG T . splicing . . . 5.90 5.90
4 TET2 106157791 . G T NM_001127208:exon3:c.2692G>T:p.G898X stopgain . . . 6.35 6.35
2 DNMT3A c.2982C>T:p.Arg882Cys    missense . . . 14.23 29.18 ND ND
2 DNMT3A p.P700L missense . . . ND ND NA NA
15 IDH2 c.600A>G:p.Arg172Gly missense . . . 13.26 13.89 ND ND
2 CD28 204591675 C A . NM_006139:exon2:c.372C>A:p.D124E missense extracellular . . 7.4 11.96
3 CTNNB1 NM_001904:exon8:c.1147T>A:p.W383R missense . yes . 3.58
3 RHOA 49412969 C A . NM_001664:exon2:c.54G>T:p.K18N missense GTP binding . . 7.42 8.44
3 RHOA 49412973 C A rs11552761 NM_001664:exon2:c.50G>T:p.G17V missense GTP binding yes . 21.98 22.00 8.98 12.31
6 FYN 111982968 G A . NM_153047:exon11:c.1579C>T:p.Q527X stop gain . . . 4.95 6.00
7 GTF2I 74150975 G T . NM__032999:exon18:c.1569G>T:p.R523S missense . . . 17.16 19.10
9 CDKN2A 21968733 C G . NM_001195132:exon3:c.495G>C:p.R165S missense yes 44.33 48.25
16 CREBBP 3781878 T C . NM_004380:exon29:c.4789A>G:p.K1597E missenseCBP/p300-typ  HAT; modified residue N6-acetyllysine . . 3.00
19 NLRP4 56369244 C T rs117212164 NM_134444:exon3:c.485C>T:p.T162M missense NACHT domain yes . 46.53 46.07
20 PLCG1 39792584 C T . NM_182811:exon11:c.1034C>T:p.S345F missense PI-PLC X-box domain yes . 6.25 6.25 3.70 4.00
20 PLCG1 39794139 C T . NM_182811:exon15:c.1559C>T:p.S520F missense PH 2; first part yes . 4.48 4.00
Patient 1 Patient 2 Patient 3 Patient 4
Table S8. Targeting Deep sequencing of 4 patients with paired samples . One patient from the discovery cohort (patient 1) and three patients from the extended cohort (patients 2 to 4) had samples harvested at diagnosis and in refractory state (patients 1 and 2, at 2.5 and 1 months) or at relapse (patients 3 and 4, at 13 and 7 months). 
Samples from patients 2 to 4 were TDS using the panels from the extended cohort. Data for TET2 , DNMT3A  and IDH2  are from a previous study. Both samples from patient 1 were TDS using the same panels as for the extended cohort plus a modified panel comprising TET2 , DNMT3A  and IDH2 . Numbers indicate the Variant Frequency, while 
colors indicate the type of mutation (red: missense; brown: stop gain; blue: freameshift deletion).  ND: not determined; NA: not applicable.
TCR-related genes mutations
N 42 43 p value test
sex
male 26 62% 24 56% 0.66 F
female 16 38% 19 44%
median age (quartile) 67 54-75 64 58-71 0.46 F
diagnosis
AITL 36 86% 36 84% 1 MW
TFH like PTCL 6 14% 7 16%
stage
I 0 0% 0 0% 0.45 F
II 0 0% 1 3%
III 12 32% 9 23%
IV 26 68% 30 75%
LDH
>N 29 78% 23 64% 0.2 F
≤N 8 22% 13 36%
hemoglobin
<10 g/dL 11 32% 10 30% 1 F
≥10 g/dL 23 68% 23 70%
platelets
<100000 3 9% 1 3% 0.62 F
≥100000 31 91% 29 97%
hypergammaglobulinemia
yes 12 48% 9 45% 1 F
no 13 52% 11 55%
Direct coombs test
positive 12 57% 16 67% 0.55 F
negative 9 43% 8 33%
ECOG
0-1 19 50% 20 57% 0.64 F
2-4 19 50% 15 43%
B symptoms
yes 25 68% 26 68% 1 F
no 12 32% 12 32%
IPI
0-2 6 16% 11 28% 0.27 F
3-5 32 84% 28 72%
First line chemotherapy
anthracyclin based 33 89% 26 67% 0.03 Khi2
Others 4 11% 13 33%
Frontline auto SCT
yes 4 10% 5 13% 0.73 F
no 35 90% 33 87%
5 years OS 29% 43% 0.36 log rank
Response to treatment*
CR 16 57% 18 72% 0.11
PR 5 18% 6 24%
SD 0 0% 0 0%
PD 7 25% 1 4%
Early progression *
yes 11 33% 2 8% 0.02 F
no 22 67% 24 92%
5 years OS* 33% 46% 0.56 log rank
5 years PFS * 21% 24% 0.11 log rank
* anthracyclin based therapy
SCT:stem cell transplantation,CR complete response, PR partial response, SD stable disease, PD 
progressive disease, F: Fisher, MW: Mann Whitney
mutant WT statistics
Table S9. Summary and comparison of the clinical features of the 85 patients of the 
extended cohort (72 AITL and 13 TFH-like PTCL, NOS cases) with (TCR_Mut) or without 
(TCR_WT) mutations in TCR-related genes (49% vs 51%).
* indicates analysis performed on anthracyclin based treated population
